Upper Small Intestinal Protein Sensing in the Regulation of Glucose Homeostasis
by
Sophie Claire Hamr
A thesis submitted in conformity with the requirements for the degree of Master of Science
Department of Physiology University of Toronto
© Copyright by Sophie Hamr (2016)
ii
Upper small intestinal protein sensing in the regulation of glucose
homeostasis
Sophie Claire Hamr
Master of Science
Department of Physiology University of Toronto
2016
Abstract
High-protein diets improve glucose control in both healthy and type 2 diabetic
individuals. Given that upper intestinal lipids trigger a pre-absorptive, gut-brain-liver
neuronal axis to suppress glucose production (GP), it is urgent to assess the potential
glucoregulatory capacity of intestinal protein sensing. We here demonstrate that in
healthy rodents in vivo, upper small intestinal infusion of protein hydrolysate improved
intravenous glucose tolerance. This was due at least in part to insulin-independent
effects on the liver, given that the same infusion suppressed hepatic GP during a basal-
insulin euglycemic clamp. Co-infusion of tetracaine reversed the ability of protein to
improve glucose tolerance, indicating that a neuronal network is initiated at the level of
the gut to regulate glucose homeostasis. Collectively, these findings show for the first
time that pre-absorptive protein sensing in the upper small intestine improves glucose
tolerance by triggering a neuronal network to lower GP.
iii
Acknowledgments
I would like to acknowledge my supervisor, Dr. Tony Lam, as well as my MSc
committee members Drs. Nicola Jones and Thomas Wolever, for their guidance and
support throughout my graduate studies. I would also like to thank all of the past and
present members of the Lam lab for their direction and assistance with my studies and
for their unconditional moral support, particularly Dr. Frank Duca, Dr. Brittany
Rasmussen and Paige Bauer for their work on this project.
iv
Table of Contents Chapter 1 Introduction ................................................................................................... 1
1.1 Obesity and diabetes ............................................................................................ 1 1.2 Dietary protein and metabolic homeostasis .......................................................... 3 1.3 Intestinal nutrient sensing in the regulation of metabolic homeostasis ................. 7
1.3.1 Control of food intake ............................................................................... 11 1.3.2 Regulation of glucose homeostasis ......................................................... 14 1.3.3 Dysregulation in obesity and diabetes ..................................................... 18
1.4 Intestinal protein sensing .................................................................................... 22 Chapter 2 Hypothesis and Aims ................................................................................. 26 Chapter 3 Materials and Methods ............................................................................... 29
3.1 Animals .............................................................................................................. 29 3.2 Surgical Procedure ........................................................................................... 29
3.2.1 Preparation of cannulae ........................................................................... 29 3.2.2 Cannulation surgery ................................................................................. 30
3.3 Intestinal infusions and treatments ................................................................ 32 3.4 Intravenous glucose tolerance test ................................................................. 33 3.5 Pancreatic (basal insulin) euglycemic clamp ................................................. 34 3.6 Biochemical analysis ........................................................................................ 35
3.6.1 Plasma glucose ........................................................................................ 35 3.6.2 Plasma amino acids ................................................................................. 35 3.6.3 Plasma [3-3H]-glucose specific activity ..................................................... 37
3.7 Tracer-dilution calculations ............................................................................. 37 3.8 Statistical analysis ............................................................................................ 38
Chapter 4 Results ......................................................................................................... 40 Chapter 5 Discussion ................................................................................................... 54 Chapter 6 References ................................................................................................... 65
v
List of Tables
Table 1: Typical amino acid content of Casein enzymatic hydrolysate from Sigma-
Aldrich (Product
22090).................................................................................................51
Table 2: Body weight and cumulative post-surgical food intake of the groups of rats that
underwent either the intravenous glucose tolerance test or clamp
protocol...................52
Table 3: Plasma glucose concentrations during the basal insulin euglycemic
clamp.....53
vi
List of Figures
Figure 1: Intestinal nutrient sensing in the regulation of metabolic
homeostasis............25
Figure 2: Schematic of the working
hypothesis..............................................................28
Figure 3: Gut infusion-IVGTT protocol to evaluate the effects of upper small intestinal
protein sensing on glucose
tolerance.............................................................................47
Figure 4: Upper small intestinal infusion of protein improves glucose
tolerance............48
Figure 5. Upper small intestinal casein hydrolysate increases the glucose infusion rate
during the basal insulin euglycemic
clamp.....................................................................49
Figure 3: Gut infusion-IVGTT protocol to evaluate the effects of upper small intestinal
protein sensing on glucose
tolerance.............................................................................50
vii
List of Abbreviations ACS Acyl-CoA synthetase AUC Area under the curve CCK Cholecystokinin CD36 Cluster of differentiation 36 DPP-IV Dipeptidyl Peptidase-4 DVC Dorsal vagal complex EEC Enteroendocrine cell ENS Enteric nervous system FXR Farnesoid X receptor GI Gastrointestinal GLP-1 Glucagon-like peptide 1 GIP Glucose-dependent insulinotropic peptide GIR Glucose infusion rate GPCR G-protein coupled receptor HbA1c Glycated hemoglobin IVGTT Intravenous glucose tolerance test i.p. Intraperitoneal LCFA Long-chain fatty acid NMDA N-methyl-D-aspartate NTS Nucleus of the solitary tract OGTT Oral glucose tolerance test OLETF Otsuka-Long-Evans-Tokushima Fatty PepT1 Peptide transporter 1 PLC Phospholipase C POMC Pro-opiomelanocortin PKA Protein kinase A PKC Protein kinase C PYY Peptide YY Ra Rate of glucose appearance Rd Rate of glucose disappearance SD Sprague Dawley SGLT-1 Sodium-glucose cotransporter 1
viii
Published Manuscripts that contributed to this thesis
Hamr SC, Wang B, Swartz TD and Duca FA. Does nutrient sensing determine how we
“see” food? Curr Diab Rep 15(6):604 (2015).
Duca FA, Bauer PV, Hamr SC and Lam TK. Glucoregulatory relevance of small
intestinal nutrient sensing in physiology, bariatric surgery and pharmacology. Cell Metab
22(3):367-80 (2015).
Bauer PV, Hamr SC and Duca FA. Regulation of energy balance by a gut-brain axis
and involvement of the gut microbiota. Cell Mol Life Sci 73(4):737-55 (2016).
1
Chapter 1
Introduction
1.1 Obesity and diabetes
Over 700 million individuals are obese, and over 300 million have type 2 diabetes
worldwide, rendering a state of global epidemic1,2. Given that obesity and diabetes are
associated with a number of life-threatening co-morbidities, and collectively cost the
Canadian healthcare system over $20 billion per year3,4, there is an urgent need to
understand their pathologies in hopes to develop successful treatments.
The etiologies of these two diseases are complex and interconnected given that
approximately 80% of type 2 diabetic individuals are overweight or obese5. Obesity and
diabetes are linked to a number of genetic and environmental factors, which collectively
lead to a dysregulation in the homeostatic control of energy balance and glucose
homeostasis. In healthy individuals, energy homeostasis is tightly regulated by a
multitude of interconnected signaling networks, which integrate signals of energy status
and regulate exogenous nutrient intake and endogenous nutrient metabolism,
accordingly. The classical view of glucose regulation and of diabetes development is an
islet-centered view, whereby blood glucose levels are primarily regulated by the
pancreatic hormones insulin and glucagon. Insulin resistance develops at the level of
peripheral tissues, leading to a compensatory increase in pancreatic insulin secretion.
2
As insulin resistance worsens, β-cell exhaustion occurs and insulin secretion no longer
compensates, resulting in hyperglycemia and a diagnosis of type 2 diabetes6. However,
50% of glucose tolerance is accounted for by insulin-independent mechanisms7, which
remain incompletely understood. Schwartz et al. recently proposed the importance of a
“brain-centered glucoregulatory system,” whereby the brain senses circulating nutrients
to regulate plasma glucose independently of insulin8. Indeed, nutrient sensing
mechanisms are an important form of insulin-independent regulation on energy
homeostasis.
Interestingly, more recent evidence brings to light the importance of nutrient sensing by
the gastrointestinal (GI) tract, indicating that nutrients generate critical negative
feedback on energy homeostasis upon initial contact with the body9. The impact of GI
or “gut” nutrient sensing on glucose homeostasis is highlighted by the fact that
metformin, the most widely prescribed drug for the treatment of type 2 diabetes, has
been found in both rodents and humans to exert effects on glycaemia via a gut-
localized site of action10,11. Further, when the GI tract is surgically re-arranged to treat
obesity, redirecting nutrient flux and implicating distal intestinal nutrient sensing, a drop
in plasma glucose levels occurs almost immediately, prior to any weight loss12,13.
Finally, pharmacological treatments increasing levels of the nutrient-stimulated gut
hormone glucagon-like peptide 1 (GLP-1) have proven effective in regulating glycaemia
in type 2 diabetic individuals14. While the mechanisms underlying these therapies
remain incompletely understood, they collectively implicate an urgent need to further
3
elucidate intestinal nutrient signaling in the regulation of glucose homeostasis and
pathogenesis of obesity and diabetes.
1.2 Dietary protein and metabolic homeostasis
In comparison to the increasing knowledge of how carbohydrates and lipids regulate
glucose homeostasis, the effects of dietary proteins remain less clear. Numerous
studies show that intravenous infusion of amino acids in a hyperinsulinemic,
euglycemic condition induces acute insulin resistance at the level of glucose uptake by
peripheral tissues15-19. In vitro studies in isolated myocytes indicate that amino acids
inhibit insulin-stimulated glucose uptake likely via competitive inhibition of glucose
oxidation (glycolysis)20-22, activation of mTOR23, and inhibition of the insulin signaling
pathway24. Interestingly, however, these findings are not consistent, given that others
found that elevating plasma amino acids had no effect on glucose uptake during a
hyperinsulinemic clamp in healthy men25, and actually increased glucose uptake to
lower glucose levels during unclamped hyperinsulinemia26. Thus, in order to examine
how dietary protein affects glucose turnover in the context of high-protein feeding,
Rossetti et al pair-fed rats either a high-protein (60% protein) or low-protein (18%
protein) diet27. Following 10 days of dietary intervention, rats fed the high-protein diet
had increased fasting glucose levels and decreased insulin sensitivity during a
hyperinsulinemic clamp at the levels of both hepatic glucose production and peripheral
glucose uptake27. This study suggests that acutely increasing dietary protein intake
may be detrimental to glucose homeostasis, due to amino acid-induced insulin
4
resistance. However, as described below, longer dietary interventions in fact show that
high protein feeding improves energy balance and glucose control, suggesting that
dietary proteins may exert other, yet to be identified effects that positively impact
metabolic homeostasis.
High-protein diets have been widely prescribed as a dietary intervention in overweight
individuals, and over a 6-month test period, high-protein diets have more successful
weight loss outcomes than conventional, high-carbohydrate weight-loss diets28-30.
These high-protein diet-treated individuals not only experience a greater overall weight
loss, but also display decreased fat mass and reduced fasting plasma free fatty-acids,
triglycerides and cholesterol29,30, indicating an overall improvement in lipid
homeostasis. These results were confirmed in healthy rodents, where a 42-day high-
protein diet reduced body weight and fat mass accumulation compared to a low-protein
diet31. Interestingly, individuals fed a high-protein weight-loss diet often have
corresponding increases in insulin sensitivity and lowering of glycated hemoglobin
(HbA1c)28,29,32,33, suggesting that increasing dietary proteins can improve glucose
homeostasis in addition to their weight-loss properties. Indeed, when Samaha and
colleagues followed up after 1 year of high-protein versus high-carbohydrate weight-
loss dieting, the high-protein group displayed lower levels HbA1c despite no persisting
effects on body weight34. However, improvements in glucose homeostasis following
long-term high-protein feeding may be secondary to the initial weight-loss, given that
modest weight loss per se is associated with improved glycemic control35. Thus, it is
important to look at the effects of short-term high-protein feeding independent of any
5
weight loss. On this note, when subjects were fed a weight-maintenance diet for 5
weeks, a high-protein diet improved glucose tolerance and HbA1c levels compared to a
high-carbohydrate diet, independent of any change in body weight36. Along with an
epidemiological analysis linking higher dietary amino acid intake with a lower risk of
type 2 diabetes37, these findings highlight the importance of looking more closely at the
effects of high-protein feeding to regulate blood glucose.
Paralleling these human studies, rodents fed a high milk-protein diet for 6 months
exhibited lower fasting plasma glucose and improved glucose tolerance as assessed
by an oral glucose tolerance test (OGTT) compared to rodents fed a normal-protein
diet38. However, it is important to note that in this study, rats were fed the diets ad
libitum, resulting in a 13% lower total food intake in the high-protein diet group38.
Indeed, both rodents and humans commonly exhibit lower food intake in response to a
high-protein diet31,33,39. Thus, in a follow up study, rats were pair-fed to look at the
effects of high-protein feeding independent of effects on food intake. In this context,
high-protein feeding no longer decreased fat mass, however the high-protein-fed rats
displayed persistent improvements in glucose tolerance and fasting plasma glucose40.
This study provides strong evidence that dietary protein can regulate glucose
homeostasis independent of effects on food intake and body weight.
In an acute setting, rats fasted for 24 hours and fed either a standard mixed meal or an
equivalent caloric load of protein hydrolysate experienced a much lower glucose
6
response to the protein meal41. However, in this case, it is impossible to distinguish the
glucose-lowering effects of the protein per se from the coinciding lack of dietary
carbohydrate contributing to the glucose response. Indeed, this variable must also be
considered in the case of the high-protein diet models described earlier, given that
protein was always substituted for carbohydrates in these diets. Thus, a model to look
at the glucose-lowering effects of protein per se is presented in studies where protein is
administered in addition to a standard meal. In one such study, overnight-fasted human
subjects consumed a standard maltodextrin beverage, with or without the addition of
protein hydrolysates42. The addition of protein lowered the glucose response to the
maltodextrin beverage, despite the equal contribution of carbohydrates and the higher
caloric load42. This phenomenon is mirrored by two similar studies where protein was
administered in the form of a whey-protein beverage either directly or 30 minutes prior
to a standard meal, while control groups did not receive a pre-load. In both cases, pre-
loading with a whey protein bolus lowered the glucose response to the subsequent
meal43,44. It is interesting to note that although amino acids stimulate insulin secretion,
the lower glucose response observed in the study by Akhavan et al was not associated
with higher insulin levels43. Thus, it would seem that the additional dietary protein load
exerts insulin-independent effects on glucose regulation in order to improve glucose
tolerance during the subsequent meal.
Our laboratory recently investigated this insulin-independent, protein-induced regulation
of glucose homeostasis. Healthy, male Sprague-Dawley rats were overnight-fasted and
fed a 19 kcal meal with either 20% or 60% calories from protein (milk-derived casein).
7
While the total calorie intake, rate of food intake, and insulin response were indeed
identical between groups, the 60%, high-protein diet resulted in a lower plasma glucose
response from 30-60 minutes post meal initiation45. Interestingly, although the insulin
response was the same, the high-protein meal increased plasma glucagon whereas the
low-protein meal did not. Indeed, glucagon signaling was partially responsible for the
glucose-lowering effects of protein, as hindbrain glucagon receptor blockade reversed
the improvement in glucose response seen at 60 minutes45. This is consistent with the
previously documented glucagon-stimulating effects of protein and glucose-lowering
effects of brain glucagon signaling45-47. However, it is important to note that glucagon
receptor blockade did not reverse the glucose-lowering effects of high-protein feeding
during the earlier time-points, indicating that there are additional, potentially insulin- and
glucagon-independent mechanisms at play. Given that this glucose-lowering response
is robust within just 30 minutes of feeding, one could speculate that negative feedback
mechanisms arise at the level of the gut upon interaction with incoming nutrients. This
theory is in fact not unprecedented given that, as described below, sensing of nutrients
such as protein by the GI tract can initiate rapid and potent negative feedback on
whole-body metabolic homeostasis.
1.3 Intestinal nutrient sensing in the regulation of metabolic homeostasis
The GI tract is the primary site of interaction between incoming nutrients and the body,
providing a site for early negative feedback on metabolic homeostasis. The extensive
8
neural and humoral connectivity of the gut wall to other important energy-regulating
areas, such as the brain, allows it to effectively relay information about incoming
nutrients in order to prevent energy excess upon nutrient absorption into the circulation.
The upper small intestine, where the majority of nutrient absorption occurs, is the major
feedback site responsible for energy regulation48.
Nutrient signaling is mediated by the release of gut peptide hormones from
enteroendocrine cells (EECs). EECs, expressed throughout the gut epithelial mucosa,
projecting their apical surfaces into the intestinal lumen, allowing them to act as
chemoreceptors, detecting nutrients predominantly via cell-surface G-protein coupled
receptor (GPCRs) or solute transporters49. In response to the detection of nutrients,
EECs release gut peptides from their basal surfaces into intestinal capillaries. Thus, the
EEC is proposed as the gut’s nutrient-sensing cell, directly sensing luminal nutrients
and generating humoral signals in response. Gut peptide hormones are thought to be
associated with individual EEC types that differ in the gut peptides they produce and
their localization along the GI tract. The proximal small intestine expresses “I cells,”
which produce the peptide cholecystokinin (CCK), and “K-cells” that produce glucose-
dependent insulinotropic peptide (GIP), while the more distal “L cells” produce GLP-1
and Peptide YY (PYY). However, there is accumulating evidence for co-expression of
gut peptides thought to be produced in distinct cell types, suggesting that the EEC may
in fact be a single cell type that produces varying spectra of peptides depending on its
environment50,51, though this is continually debated52.
9
Specific and independent sensory and signal transduction mechanisms mediate gut
peptide release in response to individual types of nutrients. EECs express a number of
nutrient-specific GPCRs such as the fatty-acid receptors GPR4053,54 and GPR12054,55
and the amino acid and peptide-receptive calcium sensing receptor (CaSR)56, as well
as solute transporters such as sodium-glucose transporter 1 (SGLT-1)57 and peptide
transporter 1 (PepT1)58. Via these chemosensory machineries, luminal nutrients
promote the exocytosis of gut peptides through intracellular metabolism, second-
messenger signaling cascades and/or membrane depolarization59. Indeed, chemical
inhibition or genetic knockout of one of these nutrient-sensing receptors or transporters
will results in impaired CCK, GLP-1 or GIP release in response to feeding53,60-63.
However, refuting this classical model of EEC nutrient sensing, there is accumulating
evidence for indirect mechanisms through which nutrients may alternatively stimulate
gut peptide release. For example, numerous studies show that lipid absorption and
packaging into chylomicrons, and the subsequent release of Apolipoprotein A-IV from
enterocytes, is required for dietary lipids to stimulate the release of CCK and GIP64-66.
Bile acids, components of bile that are released form the liver into the intestinal lumen
in response to nutrient ingestion to aid with the solubilization and digestion of lipids,
have also been implicated in stimulating gut peptide release. Bile acids themselves
may act directly on EECs to regulate gut peptide secretion via their endogenous
receptor, the farnesoid X receptor (FXR), though the evidence to date is
contradictory67,68. Nonetheless, whether nutrients signal directly on or within EECs, or
indirectly via other cell types, the resulting release of gut peptide hormones is the first
step in the initiation of nutrient-induced negative feedback axes.
10
Upon exocytosis from EECs, gut peptides are secreted into the portal circulation to act
directly on target organs in an endocrine fashion. For example, systemic plasma CCK
levels increase in the postprandial state in both humans and rodents69,70, and the brain
expresses CCK receptors that are implicated in metabolic regulation71. The brain also
expresses GLP-1 receptors72,73, however unlike CCK, GLP-1 is rapidly degraded in
circulation by the enzyme Dipeptidyl Peptidase-4 (DPP-IV), resulting in less than 10%
of GLP-1 reaching the systemic circulation following secretion74. GLP-1 may instead
reach the brain via lymph vessels, given that in the postprandial state, lower levels of
DPP-IV and higher levels of GLP-1 are found in the lymph than in the portal vein75-77.
The gut peptide PYY is likely to signal predominantly in an endocrine fashion, given
that circulating PYY levels peak 1.5 hours after feeding and remain elevated for several
hours78. Alternatively, CCK and GLP-1, which display more transient peaks, may in fact
be more important in paracrine signaling with the gut.
The proximal small intestine is densely innervated by the vagus nerve, with afferent
fibers (projecting to the brain) far outnumbering efferent fibers79,80. Extensive evidence
indicates that the acute regulation of food intake and plasma glucose in response to
intestinal nutrients is mediated by these vagal afferents. Indeed, vagal afferents
express receptors for CCK, GLP-1 and PYY, and activation of these vagal gut peptide
receptors leads to afferent firing81. Vagal afferent dendrites innervate the lamina propria
of the gut mucosa, rather than EECs directly, indicating that gut peptides likely diffuse
to nearby vagal targets in a paracrine fashion once released81. Alternatively, neurons of
the enteric nervous system (ENS), which also express gut peptide receptors and are
11
situated in between EECs and vagal afferents, may act as an intermediate neuronal
relay82-84. One study found that the nutrient-sensing receptor GPR40 is expressed by
vagal afferent neurons themselves, suggesting that in some cases nutrients diffuse
through the gut epithelium to activate vagal afferents directly85. Nonetheless, nutrient
influx results in the activation and firing of vagal afferent neurons, which subsequently
relay a signal to the nucleus of the solitary tract (NTS) in the dorsal vagal complex
(DVC) of the hindbrain, where vagal afferents terminate86. Indeed, intraduodenal
nutrient infusion leads to c-fos activation of NTS neurons, and this response is blocked
by treatment of gut vagal afferents with the neurotoxin capsaicin87. Gut-derived signals
are integrated by the NTS, which relays to other brain areas to regulate metabolic
homeostasis accordingly88. This EECàvagal afferentàhindbrain axis mediates a wide
range of feedback systems activated by nutrients in the intestine, including important
regulation on food intake and glucose homeostasis (Figure 1).
1.3.1 Control of food intake
Fasted rats decrease their rate of feeding within minutes of meal initiation89, indicating
the presence of negative feedback on food intake before nutrients reach the circulation
(the term “pre-absorptive” hereafter refers to effects generated by nutrients prior to the
release of nutrients into the portal and systemic circulation, but not necessarily prior to
absorption by enterocytes). This pre-absorptive feedback is initiated within the small
intestine, given that a suppression of food intake is entirely absent during sham
feeding, when food is drained from gastric fistulas, never reaching the duodenum90.
12
Alternatively, infusion of a nutrient solution directly into the lumen of the duodenum
results in a rapid suppression of sham feeding91. Surgical ablation of the
subdiaphragmatic vagus or gut capsaicin treatment completely reverses the
suppressive effects of intraduodenal proteins, carbohydrates or lipids on sham
feeding92,93. Likewise, capsaicin treatment of the hindbrain blocks the effect of intestinal
nutrients to suppress sham feeding94. Together, these results indicate that the acute
feedback on food intake in response to duodenal nutrients is entirely mediated by a
vagal gutàhindbrain neuronal axis.
CCK, often referred to as the “satiety hormone,” has long been associated with acute
control of food intake in both rodents and humans95,96. In humans, intravenous infusion
of a CCK receptor antagonist delays feelings of “fullness” during a meal97, and reverses
the suppression of ad libitum food intake by intraduodenal lipid infusion98. In rodents,
CCK receptor knockout, or co-infusion of a CCK receptor antagonist, reverse vagal
afferent firing and suppression of food intake in response to intraduodenal nutrients99-
101. Likewise, peripheral (intraperitoneal; i.p.) CCK-8 (the biologically active form of
CCK) injection activates brainstem neurons to suppress feeding, and this effect is
completely abolished by intestinal capsaicin, subdiaphragmatic vagotomy, or hindbrain
capsaicin94,102,103. This CCK-mediated gutàbrainstem axis requires CCK-A (CCK-1),
but not CCK-B receptors, which are indeed expressed by vagal afferent fibers101,104,105.
Together, these results suggest that CCK produced by the gut regulates satiety entirely
via vagal CCK-1 receptors. While CCK receptors are expressed in the brain, and
intracerebroventricular CCK administration lowers feeding106, central receptors may
13
mediate pathways by centrally-produced, and not intestinally-produced CCK103, given
that central CCK-1 receptor inhibition does not block feeding suppression by intestinal
nutrients107.
Postprandial GLP-1 levels correlate with lower hunger scores in humans108, suggesting
a role for GLP-1, in addition to CCK, in the suppression of appetite. Indeed, in rodents,
i.p. GLP-1 injection suppresses food intake, and this effect is blocked by vagotomy or
capsaicin, implicating a parallel role for vagal afferent GLP-1 action in nutrient-induced
satiety109,110. In humans, intravenous GLP-1 infusion dose-dependently suppresses
energy intake during an ad libitum meal111. Patients that have undergone truncal
vagotomy surgery as a treatment for duodenal ulcers provide a comparative human
model to subdiaphragmatic vagotomized rodents, and these individuals are
characterized by impaired suppression of feeding in response to intravenous GLP-1
infusion112. Thus, there is extensive evidence that like CCK, GLP-1 released in
response to luminal nutrients acts on local, vagal afferents to trigger a gut-brain axis to
suppress feeding.
At the level of the hindbrain, the activation of NTS neurons by vagal afferents and
subsequent neuronal relay is incompletely understood, but involves N-methyl-D-
aspartate (NDMA) receptor transmission and subsequent phosphorylation of ERK 1/2
and synapsin I within the NTS113-115. The distinct neuronal populations within the NTS
that are activated by vagal afferent signaling appear to include anorexigenic pro-
14
opiomelanocortin (POMC)-expressing neurons116. Indeed, blockade of NTS
melanocortin receptor (MC4R) signaling reverses the activation of NTS ERK1/2 and
suppression of feeding in response to peripheral CCK117. NTS neurons then project to
other brainstem nuclei which contain neuronal motor output that controls the
behaviours involved in feeding, supporting a possible brainstem-isolated reflex to
control food intake. Indeed, intestinal nutrients suppress food intake in decerebrate rats
with only the brainstem intact118. However, NTS neurons also project to many higher-
order brain regions involved in the control of feeding, including the hypothalamic
arcuate and paraventricular nuclei. Indeed, Otsuka-Long-Evans-Tokushima Fatty
(OLETF) rats, which lack the CCK-1 receptor and are subsequently hyperphagic and
mildly obese, display altered hypothalamic melanocortin neuropeptides119, supporting a
role for the hypothalamus in regulation of feeding by gut peptides.
1.3.2 Regulation of glucose homeostasis
While the suppression of food intake by gut peptide-mediated nutrient sensing
mechanisms has been studied extensively, far less is known about the role of nutrient
signaling in the regulation of blood glucose. However, accumulating evidence supports
a role for the GI tract in acutely regulating whole-body glucose metabolism. The first
observation that the gut could regulate blood glucose was the discovery of the “incretin”
effect, whereby oral glucose administration results in roughly double the insulin
response compared to delivery of the same amount of glucose intravenously120.
Indeed, the gut peptides GIP and GLP-1, both secreted in response to intestinal
15
nutrients, act directly on pancreatic β-cells to stimulate glucose-dependent insulin
secretion, subsequently improving glucose tolerance121-123. Interestingly, when GLP-1
is infused intravenously, glucose tolerance improves not only through an increase in
insulin secretion but also by insulin-independent increases in glucose disposal124. In
another study, intravenous GLP-1 infusion during a basal insulin pancreatic clamp
suppressed hepatic glucose production independent of any pancreatic action125.
Although the mechanisms are unknown, these results suggest that the glucoregulatory
capacity of gut-derived signals is not in fact limited to the incretin effect. Brain GLP-1
signaling may play a role, given that central GLP-1 infusion stimulates muscle glucose
uptake independent of muscle insulin receptors126, and hypothalamic GLP-1 infusion
suppresses hepatic glucose production127. These studies suggest that gut-derived
GLP-1 may reach the brain to signal via central GLP-1 receptors to regulate blood
glucose, though again, this signaling axis could be more relevant to centrally-produced
GLP-1.
Given the implication of vagal afferent gut peptide receptors in the regulation of food
intake, vagal GLP-1 receptor signaling within the gut might also play a role in the
regulation of glucose homeostasis by GLP-1. To investigate this hypothesis, a rat
model was developed with specific knockdown of GLP-1 receptors in vagal afferent
neurons through delivery of an shRNA lentiviral vector into the nodose ganglia128. In
this rat model, a 50% knockdown of vagal afferent GLP-1 receptors resulted in
increased post-meal glucose levels following an overnight fast128, confirming that
paracrine, vagal GLP-1 signaling plays a physiological role in glucose regulation.
16
Furthermore, a low oral dose of DPP-IV inhibitor, which selectively inhibits intestinal
DPP-IV activity, increases vagal afferent firing and improves glucose tolerance, and
this effect is absent in GLP-1-/- mice129, further supporting the role of vagal GLP-1
signaling within the intestine to regulate glucose homeostasis. Of note, in addition to
innervating the gut wall, vagal afferent fibers innervate the portal vein and this is a
second site at which nutrients may trigger a gut-brain axis prior to reaching the
systemic circulation. Indeed, infusion of glucose directly into the portal vein increases
whole-body GU to lower plasma glucose, and this is blocked by co-infusion of a GLP-1
receptor antagonist130, implicating a potential role for hepatoportal GLP-1 receptors in
regulating whole-body glucose homeostasis via a gut-brain axis. Nevertheless, further
work is required to dissect intestinal and hepatoportal GLP-1 signaling in the regulation
of glucose homeostasis via a gut-brain axis.
Gut peptide regulation of glucose homeostasis is in fact not limited to the well-known
“incretin hormones” GLP-1 and GIP, as intravenous infusion of CCK increases insulin
secretion and lowers plasma glucose levels131. Indeed, β-cells express the CCK
receptor132, and CCK-/- mice display impaired insulin response to i.p. glucose
injection133. In vitro studies show that like GLP-1 and GIP, CCK stimulates insulin
secretion from β-cells by enhancing GSIS134-136. In addition, CCK-1 receptor signaling
within the intestine contributes to the glucoregulatory effects of CCK. Intraduodenal
infusion of a CCK-1 receptor inhibitor dysregulates the glucose response to mixed-meal
feeding in healthy rodents137, indicating that intestinal CCK-1 receptor signaling is in
fact required for normal glucose homeostasis during digestion.
17
In order to dissect the mechanisms through which intestinal nutrient sensing might
regulate glucose homeostasis via CCK, we examined the effect of intraduodenal
nutrient infusion on glucose kinetics during a basal insulin euglycemic pancreatic
clamp. During the clamp, intraduodenal infusion of Intralipid (a lipid emulsion) rapidly
and potently suppressed hepatic glucose production, but did not alter glucose
uptake138. This effect on glucose production was mediated by a gut-brain-liver neuronal
axis, involving vagal afferents, NMDA receptor transmission in the NTS, and the
hepatic vagal efferent138. At the level of the gut, the effect of Intralipid to lower glucose
production required esterification of long-chain fatty acids (LCFA) to LCFA-CoA by
acyl-CoA synthetase (ACS), implicating cellular uptake and subsequent metabolism of
fatty-acids, rather than activation of cell-surface receptors, in the stimulation of gut
peptide release. Co-infusion of a CCK-1 receptor antagonist or genetic knockout of the
CCK-1 receptor reversed the effects of intraduodenal lipids to suppress glucose
production, while intraduodenal infusion of CCK-8 per se suppressed glucose
production137, indicating that a release of CCK in response to intestinal LCFA-CoA
mediates this gut-brain-liver axis. Blocking duodenal PKC-δ negated the ability of
intraduodenal lipids to lower glucose production139, indicating that LCFA-CoA
stimulates the release of CCK via activation of PKC-δ, a signaling pathway that has
been confirmed in vitro140,141. Of note, intraduodenal infusion of a PKC-δ inhibitor
resulted in a dysregulation of glucose response during an un-clamped feeding
paradigm, proving the physiological relevance of this duodenal lipid-sensing pathway.
The CCK-1 receptor, a GPCR, activates both phospholipase C (PLC)- and protein
kinase A (PKA)-dependent pathways, both of which have been shown to be necessary
18
for activation of vagal afferent neurons by CCK142. During the clamp, activation of PKA
was required for intraduodenal lipids or CCK-8 to stimulate vagal afferent firing and
suppress hepatic glucose production143. Thus, a LCFAàLCFA-CoAàPKC-δ
àCCKàCCK1RàPKA signaling axis within the upper small intestine activates a gut-
brain-liver neuronal axis to suppress hepatic glucose production and maintain glucose
homeostasis in healthy rodents in vivo144. This confirms that in parallel to a gut-brain
axis to regulate food intake, pre-absorptive lipids within the intestine activate a neuronal
gut-brain-liver axis to regulate glucose homeostasis (Figure 1). Whether a similar
negative feedback axis to regulate glucose homeostasis is initiated by upper intestinal
carbohydrates or protein remains to be investigated.
1.3.3 Dysregulation in obesity and diabetes
Obesity, subsequent dysregulation of glucose homeostasis and the onset of diabetes
develop from a combination of genetic and environmental factors that disrupt that
homeostatic control of food intake and glucose homeostasis. One such environmental
factor is the overconsumption of a highly palatable “western diet” that is high in sugar
and fat. Evidence suggests that the consumption of a high-fat diet alters intestinal
nutrient-sensing pathways that, as described above, are important factors in the
regulation of energy homeostasis, and that this may in fact be an important contributor
to the development of obesity and diabetes. Understanding the precise mechanisms of
this disruption to nutrient sensing has the potential to unveil novel therapeutic targets to
restore homeostasis in disease.
19
Following 21 days of high-fat diet feeding in rats, the reduction of food intake in
response to intraduodenal fatty acid infusion is attenuated compared to rats maintained
on a low-fat diet145. Likewise, humans maintained on a high-fat diet for just 14 days are
no longer sensitive to the satiating properties of intraduodenal lipid infusion146. In
another study, 14 day high-fat diet-fed humans consuming an ad libitum meal reported
lower feelings of “fullness” and ate more than when fed a balanced diet for 14 days
beforehand147. Thus, it is evident that high-fat feeding leads to a disruption in intestinal
nutrient sensing mechanisms, at least in the regulation of food intake, but it is unclear
which precise mechanism(s) in the feedback axis might be disrupted.
There is evidence that high-fat feeding alters the expression of the GPCR’s and
transporters through which gut epithelial cells sense luminal nutrients. EECs isolated
from the small intestines of high-fat diet-fed mice have lower expression of the nutrient-
sensing transporters SGLT-1 and PepT1 as well as the fatty-acid receptor GPR120
compared to those of healthy mice148. Likewise, overweight and obese humans have
lower duodenal expression of the fatty-acid receptor GPR11954. However, in the same
study, the authors identified higher expression of duodenal cluster of differentiation 36
(CD36; a lipid transporter implicated in gut peptide release) and GPR12054,149. This is
consistent with another study in rodents, where rats fed a high-fat diet for 10 weeks
displayed higher expression of the fatty-acid receptors GPR40, GPR41 and
GPR120150. Increased fatty-acid receptor expression suggests that the disruption in
20
nutrient sensing may occur downstream of lipid receptor activation, leading to a
compensatory increase in receptor expression.
Indeed, the same obese individuals who showed increased duodenal CD36 and
GPR120 displayed decreased numbers of CCK- and GLP-1-expressing cells54.
Similarly, rats fed a high-fat diet for 10-weeks displayed lower intestinal CCK and GLP-
1 protein expression150. This suggests that high-fat feeding can lead to a decrease in
CCK and GLP-1 production, which may at least in part contribute to the disruption in
the ability of nutrient sensing to suppress food intake described above. However, of
note, the impaired satiation by oral or intraduodenal nutrients in 14-day high-fat diet-fed
humans was not in fact associated with lower release of CCK or GLP-1146,147. This
suggests that in high-fat feeding, even if nutrients are able to stimulate the release of
sufficient CCK or GLP-1, the ability of gut hormones to initiate the gut-brain feedback
axis may be impaired.
Indeed, rats fed a high-fat diet for 3 weeks do not suppress food intake in response to
i.p. CCK-8 injection at a dose that significantly reduces food intake in low-fat diet-fed
rats151. Likewise, we found that in rats fed a 3-day high-fat diet, neither intraduodenal
Intralipid nor CCK-8 infusion suppresses hepatic glucose production during the
pancreatic clamp137,138. The inability of CCK to initiative negative feedback on food
intake or glucose production implicates a potential role for resistance at the level of
vagal afferent gut peptide receptors. Indeed, 3-week high-fat diet-fed rats display
21
reduced c-fos activation of neurons in both the nodose ganglion (vagal afferents) and
the NTS in response to i.p. CCK injection or intraduodenal lipid infusion152-154,
implicating reduced neuronal sensitivity to CCK. We found that the resistance for CCK
to suppress hepatic glucose production occurred at the level of the activation of PKA
and subsequently vagal afferent firing by intraduodenal CCK143. As such, bypassing
CCK receptor activation and infusing a PKA activator directly into the duodenum
restored vagal afferent firing and suppression of hepatic glucose production143. Thus,
through unclear mechanisms, high-fat feeding disrupts the ability of CCK activation of
the CCK-1 receptor to stimulate PKA signaling within the gut (Figure 1). More work is
required to understand the precise mechanisms through which high-fat feeding disrupts
the gut-brain axis to regulate various physiological functions, and the potential to
restore intestinal nutrient signaling pathways to treat obesity and diabetes.
Evidently, intestinal nutrient sensing plays an important role in the acute regulation of
both food intake and blood glucose during feeding, and these regulatory mechanisms
are critical for the body to achieve energy homeostasis. Further, disruption of gut
nutrient sensing during high-fat feeding likely contributes to the development of obesity
and diabetes. Thus, it is crucial to further dissect the mechanisms through which
individual nutrients stimulate this gut-brain axis, and how they may contribute to the
pathology of metabolic diseases. To date, the most is known about intestinal lipid-
sensing mechanisms in the control of glucose homeostasis. Interestingly, however,
numerous studies have shown that intestinal protein is more potent than equicaloric
amounts of lipid or carbohydrate to stimulate gut peptide release155 and suppress
22
feeding91,156. In light of this, it is vital to further understand the role of dietary protein in
the gut-brain axis.
1.4 Intestinal protein sensing
High-protein diets increase circulating levels of both CCK and GLP-1157,158, and indeed,
luminal protein is a potent stimulus of the gut hormones CCK, GLP-1 and PYY158-161.
Intraduodenal infusion of protein hydrolysates or individual amino acids potently
suppresses feeding in rodents and humans91,92,161-163, the suppression of food intake by
intestinal protein requires CCK-dependent vagal afferent firing164, and high-protein diet
feeding is associated with activation of anorexigenic, CCK-responsive NTS neurons165.
However, the reduction of food intake by high-protein feeding is also associated with a
rise in GLP-1, and the potential role of GLP-1 is less clear158,166.
At the level of the intestinal epithelium, various sensory mechanisms have been
proposed to link luminal amino acids and proteins to the release of gut peptides. Gut
mucosal cells express a number of GPCRs sensitive to amino acids, oligopeptides, or
both, as well as transporters for either free amino acids or oligopeptides. While many of
these protein sensors have been linked to gut peptide release in vitro, the relative
importance of each sensor in the physiological regulation of the gut-brain axis remains
unclear.
23
T1R1-T1R3, the α-gustucin-coupled “umami” receptor that senses amino acids in taste
buds of the tongue, is also expressed throughout the small intestine, specifically by
CCK-expressing EECs, and in vitro, blocking T1R1 blunts CCK secretion in response
to a number of aliphatic amino acids167,168. Individual amino acids are taken up by an
array of transporters with varying specificities, many of which remain to be identified.
However, one such transporter, B0AT1, has been cloned in both rodents and humans
and found to transport the bulk of neutral amino acids169. B0AT1 knockout mice have
decreased intestinal amino acid signaling and insulin release in response to feeding170,
and intestinal B0AT1 expression is altered in obesity171, suggesting that this transporter
could play a role in nutrient sensing, though more work is required to fully elucidate its
role. GPR93 is a GPCR expressed throughout the gut mucosal epithelium, and
specifically by CCK-expressing cells, which senses both individual amino acids and
small peptides and has been implicated in CCK release in vitro172,173. Likewise, CaSR
is a GPCR that was originally identified as a receptor for calcium, but that also senses
amino acids and small peptides174. CaSR is expressed by primary duodenal I-cells
isolated from mice, and mediates aromatic amino acid-induced CCK release56. CaSR
has also been shown to mediate peptide-induced CCK and GLP-1 release in vitro175-
177. While each of these protein sensors has been implicated in cell lines, future studies
are required to address their physiological role in gut peptide release in vivo.
A number of the aforementioned receptors sense both amino acids and oligopeptides,
and it remains unclear whether luminal proteins usually signal in the form of free amino
24
acids, small peptides, or both, to stimulate gut peptide release during digestion. An
intraluminal free amino acid solution stimulates vagal afferent firing in rodents178 and
induces gut peptide release in humans179, suggesting that individual amino acids can
induce gut-brain signaling. However, intraduodenal protein hydrolysate infusion also
stimulates CCK-dependent vagal afferent firing180,181, and one study showed that co-
infusion of the proteolytic enzyme trypsin decreased the CCK response to protein
hydrolysates by 60%182, suggesting that proteins signal at least partially in the form of
oligopeptides. Further, one in vitro study showed that removing the lower molecular
weight fractions from protein hydrolysates, which includes free amino acids, has no
effect on its ability to induce CCK release from STC-1 cells, and that a free amino acid
solution does not in fact induce CCK release from these cells176. Along with the fact
that non-metabolizable peptidomimetics (synthetic peptides) activate EECs and
stimulate CCK release183-185, these results suggest that luminal protein may in fact
signal mainly in the form of di- and tripeptides, prior to further lysis into free amino
acids, to initiate a gut-brain negative feedback axis.
Unlike amino acid transport, the uptake of di- and tripeptides in the small intestine is
solely mediated by one molecule, PepT1. In addition to mediating enterocyte peptide
absorption, PepT1 has been localized on CCK-secreting cells and is able to elicit
voltage-gated calcium entry in response to the uptake of peptides177. Indeed, non-
metabolizable PepT1 substrates stimulate CCK release from STC-1 cells in vitro58.
Further, PepT1 inhibition blocks firing of CCK-responsive vagal afferents in response to
25
intraduodenal protein hydrolysate infusion ex vivo181, further highlighting its likely role in
the initiation of gut-brain signaling in response to luminal protein.
26
Figure 1: Intestinal nutrient sensing in the regulation of metabolic homeostasis. Luminal nutrients signal via cell-surface receptors and transporters to stimulate the
release of gut peptide hormones from enteroendocrine cells in the gut mucosa, via
receptor-induced membrane depolarization, second-messenger signaling cascades or
intracellular nutrient metabolism. Once released, gut peptides act on receptors
expressed locally by vagal afferent fibers innervating the lamina propria to induce vagal
afferent firing. Vagal afferents terminate in the NTS of the hindbrain, where neuronal
signals are relayed via the hypothalamus and/or vagal efferents to suppress food intake
and hepatic glucose production to maintain energy homeostasis. High-fat diet feeding
disrupts this nutrient-signaling axis, most likely at the level of gut peptide receptor
signaling on vagal afferents. NTS, nucleus of the solitary tract; HYP, hypothalamus.
26
Chapter 2
Hypothesis and Aims
Upper small intestinal nutrient sensing mechanisms are implicated in the regulation of
food intake and whole-body glucose homeostasis, and are disrupted in high-fat diet
feeding, potentially contributing to the development of obesity and diabetes. More
specifically, upper intestinal lipids stimulate the release of CCK, which acts on CCK-1
receptors expressed by vagal afferent neurons to signal via a gut-brain axis to
suppress feeding and a gut-brain-liver axis to suppress hepatic glucose production.
Alternatively, little is known about the role of intestinal protein sensing mechanisms to
regulate metabolic homeostasis, despite the fact that acute dietary protein intake
improves glucose homeostasis in both rodents and humans. Given that upper intestinal
protein suppresses food intake via CCK-mediated vagal afferent firing, we propose that
while in the pre-absorptive state, dietary proteins trigger a neuronal network to regulate
whole-body glucose homeostasis.
General Hypothesis: Upper small intestinal protein sensing triggers a neuronal
network to lower hepatic glucose production and maintain glucose homeostasis in
healthy rodents in vivo (Figure 2).
27
Aims:
Aim 1: To evaluate whether upper small intestinal protein sensing regulates glucose
homeostasis.
Aim 2: To investigate whether upper small intestinal protein-sensing mechanisms
regulate glucose homeostasis through direct effects on glucose uptake or glucose
production.
Aim 3: To evaluate whether a neuronal network is required for upper small intestinal
protein sensing to regulate glucose homeostasis.
28
Figure 2: Schematic of the working hypothesis. Luminal protein is sensed by the
gastrointestinal tract prior to absorption into the portal circulation, signalling to activate
a neuronal network within the gut wall. This signal is then relayed via a gut-brain-liver
neuronal axis to directly suppress hepatic glucose production, improving whole-body
glucose tolerance. NTS, Nucleus of the solitary tract; NMDA; N-methyl D-aspartate;
DVC, dorsal vagal complex.
29
29
Chapter 3
Materials and Methods «
3.1 Animals
For all studies, male Sprague-Dawley rats were obtained from Charles River
Laboratories (Montreal, QC, Canada) at 8-weeks of age (250-270g). Rats were
individually housed and maintained for six days with a standard 12-hour light-dark cycle
and ad libitum access to water and rat chow (Harlan Teklad; % calories: 16% fat/60%
carbohydrate/24% protein; total caloric value: 3.1 kcal/g) in order to acclimatize to our
facilities prior to surgical manipulation. All animal protocols were reviewed and
approved by the Institutional Animal Care and Use Committee at the University Health
Network.
3.2 Surgical Procedure
3.2.1 Preparation of cannulae
Duodenal cannula: 18 cm of 0.04 inner-diameter/0.085 outer-diameter silicon tubing
(Sil-Tec) was overlapped with 1 cm of smaller, 0.025 inner diameter/0.037 outer-
diameter silicon tubing (Sil-Tec). A 1-cm2 piece of polypropylene mesh (Bard Davol)
30
30
was glued to the cannula at the intersection of the two tubing sizes, such that the small
tubing passed through a hole in the center of the mesh square. Vascular cannulae: 15
cm of PE50 polyethylene tubing (Clay Adams) was fitted with a 1.5 cm cuff extension of
15 mm inner-diameter Silastic silicon tubing (Dow Corning).
3.2.2 Cannulation surgery
Rats were anesthetized with an intraperitoneal injection of a cocktail of ketamine (60
mg/kg; Vetalar, Bioniche) and xylazine (8 mg/kg; Rompun, Bayer). The abdominal and
neck regions were shaved and sanitized with 70% ethanol and 10% providine-iodine
solution (Betadine). A 4 cm laparotomic incision was made along the ventral midline
through both the skin and abdominal muscle wall, exposing the GI tract within the
peritoneal cavity. The duodenum was isolated 6 cm distal to the pyloric sphincter. A
small hole was made in the intestinal wall using a 21-guage needle in an area with the
least vascularization to minimize bleeding, and the intestinal cannula was inserted into
this hole and anchored to the outer surface of the duodenum by applying tissue
adhesive (3M Vetbond) to the surrounding mesh. The duodenal cannula was flushed
with saline to ensure that the infusion flowed into the lumen of the duodenum with no
leakage. The duodenum was then repositioned within the peritoneal cavity and the
abdominal wall was closed with 4-0 silk sutures such that the cannula exited through
the abdominal wall between 2 continuous sutures. A 1.5 cm incision was made in the
back of the neck and the cannula was tunneled subcutaneously from the abdomen,
exiting the incision in the neck. The neck and abdominal incisions were closed with 4-0
silk sutures and the end of the cannula, which now exited through the back of the neck,
was closed with a metal pin.
31
A 3 cm incision was then made in the front of the neck, and through blunt dissection of
fat, connective tissue and muscle, the right jugular vein was isolated. The vessel was
ligated at the cranial end and loosely tied at the caudal end using 4-0 sutures, and the
ligatures were pulled taught to prevent blood flow in the isolated segment of the vessel.
A small incision was made in the vessel wall using microscissors, and a vascular
cannula filled with 1% heparinized saline was inserted into the vessel lumen until it
reached a position where blood freely flowed into the cannula when an attached
sampling syringe was pulled back. The cannula was then secured in place by
tightening the loosely tied ligature around the vessel and cannula. This procedure was
repeated with the right carotid artery. The two cannulae were then tunneled
subcutaneously with a 16-guage needle so that they exited the back of the neck on
either side of the intestinal cannula. The neck incision was closed with 4-0 sutures, and
the vascular cannulae were filled with 10% heparin solution to prevent clotting and
closed with metal pins. 10 mL of 0.9% saline was injected subcutaneously to help with
recovery and rats were returned to their cages.
Rats were given 4 days to recover from surgery with ad libitum access to water and
regular chow. The intestinal cannula was flushed with saline daily to prevent clogging.
Food intake and body weight were monitored daily and rats recovered to at least 90%
of their pre-surgical body weight prior to experiments.
32
3.3 Intestinal infusions and treatments
The following treatments were infused into the upper small intestine via the indwelling
cannula during the in vivo experiments, at a rate of 0.12 ml/min for 1 minute to fill the
dead space of the cannula followed by 0.01 ml/min to a total of 50 minutes: 1) 0.9%
saline, 2) 8% (w/v) casein hydrolysate 3) tetracaine (0.01 mg/mL) and 4) 8% (w/v)
casein hydrolysate + tetracaine (0.01 mg/mL). All of the treatments were adjusted to pH
5, which is the native pH of the rat upper small intestine186.
Casein was selected for its broad amino acid composition and because it is a common
dietary protein source. The hydrolyzed form of casein protein is composed of small
peptides and free amino acids and most closely resembles the partially digested form
in which dietary proteins reach the upper small intestine during digestion. The typical
amino acid analysis of casein hydrolysate (Sigma-Aldrich) can be seen in Table 1. The
dose of 8% (w/v) casein hydrolysate (0.32 kcal/mL) was selected because
intraduodenal 8% peptone stimulated vagal firing and suppressed food intake in
rodents in vivo181,187. 3.2 g of casein hydrolysate (Sigma-Aldrich) was solubilized in 40
mL of saline by lowering the pH to 1 through titration with 10 M HCl and subsequently
raising the pH to 5 through titration with 10 M NaOH.
The tetracaine dose was based on a previous study where 0.01 mg/min tetracaine
blocked intraduodenal lipid infusion to regulate glucose homeostasis138. Tetracaine
33
(Sigma-Aldrich) was dissolved in DMSO in a stock solution of 200 mg/mL, and 22.5 µL
of this stock solution was added to 3 mL of either saline or 8% casein hydrolysate.
3.4 Intravenous glucose tolerance test
Food was removed at 5 pm the night before the glucose tolerance test for an overnight
fast. Experiments took place at 10:00 AM. The experimental protocol can be seen in
Figure 3A. The intraintestinal infusion was initiated at t=-15 at a rate of 0.12 mL/min for
1 minute to fill the dead space of the intestinal cannula, followed thereafter by a rate of
0.01 mL/min, administered using a Harvard Apparatus PHD 2000 syringe pump. At t=0,
the glucose injection was administered (0.25g/kg, 20% glucose solution), over 10
seconds, via the jugular vein cannula. 0.4 mL blood samples were drawn from the
carotid artery cannula at t=-15, t=0 (prior to the glucose injection), t=2, t=5, and every 5
minutes thereafter until t=35, for plasma glucose and amino acid analysis (see below).
The experiment was terminated at t=35, or the end of 50 minutes of gut infusion. At the
end of the 50-minute experiment, rats were anesthetized via intravenous administration
of ketamine, and a 0.5 mL portal vein blood sample was drawn for plasma amino acid
analysis.
34
3.5 Pancreatic (basal insulin) euglycemic clamp
Rats were restricted to 15 g (~47 kcal) of food the night prior to the clamp experiment,
which took place at 9:00 AM. The clamp protocol can be seen in Figure 4A. An
intravenous infusion of [3-3H]-glucose (40 µCi bolus; 0.4 µCi/min; Perkin Elmer) was
initiated at t=0 and continued for the duration of the 200-minute experiment. From t=60
to t=90, once the [3-3H]-glucose has reached steady-state in the rat, 0.2 mL blood
samples were drawn every 10 minutes from the carotid artery for plasma glucose
analysis (see below) in order to obtain basal plasma glucose readings. At t=90, the
pancreatic clamp was initiated through continuous intravenous infusion of somatostatin
(3 µg/kg/min; Bachem) and insulin (1.2 mU/kg/min; porcine insulin; Sigma-Aldrich).
Somatostatin was infused to inhibit all endogenous insulin secretion while the
exogenous insulin infusion replaced insulin at basal levels. An intravenous infusion of
exogenous glucose (25% solution) was also initiated at t=90. Plasma glucose readings
were obtained every 10 minutes from t=90-200, and the exogenous glucose infusion
rate was adjusted as required to maintain euglycemia according to the basal glucose
readings. During the final 50 minutes of the experiment (t=150-200), the upper small
intestinal infusions were administered as previously described above. Additional 50 µL
plasma samples were obtained at all of the 10-minute time points for later plasma
specific activity analysis. At the end of the experiment, at time t=200, rats were
anesthetized via intravenous administration of ketamine, and a 0.5 mL portal vein blood
sample was drawn for plasma amino acid analysis. All infusions were administered
using a Harvard Apparatus PHD 2000 syringe pump.
35
3.6 Biochemical analysis
3.6.1 Plasma glucose
During in vivo experiments, blood samples were collected into heparinized Eppendorf
tubes and centrifuged (6000 rpm, 1 min) to separate the plasma. 10 µL of plasma was
then analyzed using a GM9 Glucose Analyzer (Analox Instruments), which utilizes the
glucose oxidase method, in order to obtain plasma glucose readings in situ.
3.6.2 Plasma amino acids
A protocol to measure plasma amino acid concentrations using the colorimetric
ninhydrin reaction was adapted from 188. Briefly, the assay is based on the principle that
ninhydrin reacts with equal affinity to the α-amino nitrogen groups of all amino acids,
with the exception of profile, producing a purple colour. This colour change can be
measured using a spectrophotometer and compared to known concentrations of α-
amino acids, resulting in a measure of total α-amino acids in the sample.
The specific protocol was as follows: The plasma samples were first deproteinized such
that the α-amine groups in the samples would be indicative of only free α-amino acids.
50 µL of plasma in 350 µL of ddH2O was deproteinized through the addition of 50 µL of
36
10% (w/v) sodium tungstate (Sigma-Aldrich) and 50 µL of 2N HCl, with successive
mixing. After standing for 5 minutes, samples were centrifuged (13000 rpm, 5 min,
4°C). 250 µL of supernatant was then combined with 125 µL of cyanide-acetate buffer
(pH 5.2) containing: 114.65 g sodium acetate (Sigma-Aldrich), 500 mL ddH2O, 36 mL
glacial acetic acid, 5g disodium EDTA (BioShop) and 20 mL cyanide solution (490 mg
sodium cyanide [Sigma-Aldrich] in 1 L ddH2O). 125 µL of ninhydrin reagent (3% (w/v)
ninhydrin [Sigma-Aldrich] in 2-methoxyethanol [Sigma-Aldrich]) was added. Tubes were
mixed and capped, and then heated in a boiling water bath for 15 minutes. Immediately
upon removal from the water bath, 3.75 mL cold diluent (50% isopropanol in ddH2O)
was added. Samples were mixed thoroughly by inversion, and transferred to 1 cm
cuvettes. In addition to the plasma samples, a “blank” sample was prepared as
described above but with 50 µL ddH2O replacing the 250 µL of deproteinized plasma,
and a “standard” sample was prepared using 50 µL of stock amino acid solution (26.8
mg glycine [BioShop] in 100 mL ddH2O) replacing the deproteinized plasma. All
cuvettes were read in a spectrophotometer (Genesys 10S VIS, Thermo Scientific) at
570 nm. Given that the standard sample contains a known concentration of 5 mg α-
nitrogen/100 mL, the following formula was then used to calculate the concentration of
α-nitrogen in the samples based on their absorbencies (E):
Plasma α-N (mg/100 mL) = (E test) – (E blank) X 5 (E standard) – (E blank)
37
3.6.3 Plasma [3-3H]-glucose specific activity
50 µL plasma samples were deproteinized through the addition of 100 µL Ba(OH)2 and
100 µL ZnSO4, vortexing, and centrifugation (13200 rpm, 5 min, 4°C). The supernatant
was then transferred to scintillation vials without lids and left for 48 hours to evaporate
under a fumehood. Evaporation rids the samples of water containing [3H] as a product
of glycolysis, such that only [3-3H]-glucose will contribute to the radioactivity in the
sample. 7.5 mL of Bio-Safe Scintillation Cocktail (Research Products International
Corp) was then added to the dry samples and the vials were counted in a LS6500
Multipurpose Scintillation Counter (Beckman Coulter).
3.7 Tracer-dilution calculations
The constant, radioactive [3-3H]-glucose tracer infusion reaches steady state in the
plasma and tissues of the rat within one hour. At this point, a steady state formula can
be applied to calculate glucose uptake and glucose production, whereby the rate of
glucose disappearance (Rd) is equal to the rate of endogenous glucose appearance
(Ra). The specific activity of the plasma samples collected during the basal period of
the clamp (t=60-90) can therefore be used to calculate glucose uptake and glucose
production at each time point as follows:
38
Ra = Rd = Tracer infusion rate (µCi/min) = Rates of Glucose production Specific activity (µCi/mg) and uptake (mg/kg/min)
During the clamp, when the exogenous glucose infusion is introduced, the rate of
glucose production must be calculated by subtracting the exogenous glucose infusion
rate (GIR), as follows:
Ra + GIR = Rd Ra = Rd – GIR = Rate of glucose production (mg/kg/min)
3.8 Statistical analysis
For the intravenous glucose tolerance test, the glucose concentration over time was
compared using a two-way anaylsis of variance (ANOVA) and was followed by a
Tukey’s post-hoc test when comparing more than two groups. The area under the
curve (AUC) was calculated with Prism software (GraphPad) as compared using an
unpaired Student’s t-test when comparing two groups or a one-way ANOVA when
comparing more than two groups. For the pancreatic clamp/tracer-dilution data
analysis, an average from t=60-90 was used as the “basal” values and an average from
t=180-200 was used as the “clamp” values. Comparisons between basal versus clamp
39
glucose uptake and glucose production were made using an unpaired Student’s t-test.
For plasma amino acid concentrations, the concentration at t=50 was compared
between saline versus casein hydrolysate treated rats using an unpaired Student’s t-
test. Prism software (GraphPad Software Inc.) was used for all statistical calculations.
A probability of P < 0.05 was accepted as significant. Values were presented as mean
± SEM.
40
Chapter 4
Results «
Upper small intestinal protein sensing improves glucose tolerance
To investigate the effects of upper small intestinal protein sensing mechanisms on
whole-body glucose homeostasis, we first developed a protocol incorporating a
simultaneous upper intestinal protein infusion and intravenous glucose tolerance test
(IVGTT) in healthy rodents in vivo. Sprague-Dawley rats were chosen as the rodent
model to allow for future comparisons between healthy and high-fat diet-fed rodents.
Upon high-fat feeding, Sprague-Dawley rats are susceptible to the development of
hyperphagia, insulin resistance and obesity, with less variability than other rat
strains189. Accordingly, only male rats were chosen as male Sprague-Dawley rats are
more susceptible than females to high-fat diet-induced hyperphagia189, and their
metabolism is not affected by variable sexual hormone cycles. All male Sprague
Dawley rats were obtained from Charles River Laboratories at 8 weeks of age, and
given exactly six days to acclimatize to our facilities prior to surgical manipulation. It is
now well understood that environmental history influences rodents’ metabolism and
their response to dietary challenges and should therefore be controlled190. On the
seventh day in our facilities, rats underwent jugular, carotid and small intestinal
cannulation surgeries. After 4 days
41
of recovery time during which they were fed an ad libitum regular chow diet, rats were
subjected to an overnight fast (food removed at 5 pm on day 4) followed by the gut-
infusion IVGTT experiment on the morning of day 5 (Figure 3A).
The IVGTT was selected to evaluate whole-body glucose homeostasis during an upper
small intestinal protein infusion, while circulating glucoregulatory hormones change at
will. The OGTT, while commonly utilized, is confounded by the rates of intestinal
glucose absorption and gastric emptying, thus producing more variable data than an
IVGTT191, which evaluates the effects of a treatment specifically on the tolerance of
circulating glucose, controlled only by glucose uptake and glucose production.
Additionally, the IVGTT provides the possibility of future mathematical modeling of our
results using the “minimal model” system developed by Bergman and colleagues to
evaluate the relative roles of insulin-dependent and insulin–independent effects7.
Finally, and most importantly, intravenous administration of glucose bypasses the
upper small intestine and does not interfere with our intestinal treatments. Rats were
fully awake throughout the IVGTT experiments, as general anesthetics can have both
direct and indirect effects on metabolic studies192. The IVGTT protocol is summarized
in Figure 3A: Briefly, the intravenous glucose injection was administered after 15
minutes of a 50-minute intestinal infusion of the given treatment, and blood samples
taken frequently to assess plasma glucose levels. The upper intestinal treatments were
administered directly into the lumen via the small intestinal cannula, first at a rate of
0.12 mL/min for one minute to fill the dead space of the cannula with the treatment and
then at a rate of 0.01 mL/min for a total of 50 minutes. Infusion of 8% casein
42
hydrolysate for 50 minutes at this rate did not increase portal or systemic free amino
acids (Figure 3B). This is consistent with previous findings that 20% intralipid
administered into the duodenum at the same rate does not increase portal or systemic
free fatty acids138. Thus, we successfully developed an in vivo model to evaluate the
effects of pre-absorptive protein-signaling mechanisms in the upper small intestine on
the regulation of whole-body glucose homeostasis.
As assessed by the IVGTT, upper small intestinal infusion of casein hydrolysate
significantly improved glucose tolerance compared to the control group receiving
intraintestinal saline, where plasma glucose levels were significantly lower from times
10-25 (Figure 4A). Further, the integrated area under the curve (AUC) of the glucose
collapsed over time was significantly reduced in protein-treated rats compared to saline
(Figure 4B). These results were independent of any differences in body weight or
cumulative post-surgical food intake (Table 2). Given that the protein treatment did not
raise circulating amino acids, our data demonstrate that upper small intestinal protein
sensing regulates whole body glucose homeostasis to improve glucose tolerance.
43
Upper small intestinal protein sensing suppresses glucose production
An improvement in glucose tolerance during an IVGTT can be accounted for entirely by
an increase in peripheral glucose uptake and/or a suppression of endogenous glucose
production. Furthermore, the effects of intestinal nutrient sensing on either glucose
uptake or glucose production may be either dependent on, or independent of, an
incretin effect to increase insulin secretion. Thus, our lab has developed a protocol
utilizing a pancreatic basal-insulin euglycemic clamp technique in conjunction with
tracer-dilution methodology to assess the direct effects of intestinal nutrient infusions
on whole-body glucose kinetics (glucose uptake and glucose production)138 (Figure
5A). To evaluate the mechanisms through which intestinal protein improves glucose
tolerance, we administered the 50-minute upper intestinal casein hydrolysate treatment
in a clamp setting, in a new group of rats that underwent the same handling, surgery
and recovery protocol as those receiving the IVGTT. The clamp experiment took place
the morning of day 5 post-surgery, and rats were restricted to 15 g (~47 kcal) of food
the night before to ensure a similar post-absorptive status. The 200-minute clamp
protocol is summarized in Figure 5A: Briefly, the [3-3H]-glucose is infused and allowed
to reach steady state, somatostatin is infused to inhibit endogenous insulin secretion
and insulin is replaced to basal levels. In the final 50 minutes of the clamp, the 50-
minute gut infusion is administered at the same rate as during the IVGTT, and an
exogenous glucose infusion is administered as required to maintain euglycemia. At
basal circulating free amino acid and insulin levels (Figure 3B), upper small intestinal
infusion of casein hydrolysate increased the exogenous glucose infusion rate (GIR)
44
required to maintained euglycemia 5-fold compared to a control saline infusion (Figure
5B). Analysis of the tracer-dilution data revealed that this increase in GIR was entirely
accounted for by a 48% suppression of hepatic glucose production (Figure 6A,B), as
glucose uptake was unaltered (Figure 6C). There were no differences in body weight or
food intake between groups (Table 2). Thus, upper small intestinal protein sensing
regulates glucose homeostasis through directly suppressing hepatic glucose
production, independent of changes in circulating insulin.
Upper small intestinal protein sensing requires local, neuronal signaling to
regulate glucose homeostasis
Given that upper intestinal lipids suppress glucose production via a gut-brain-liver
neuronal axis138, we next evaluated the role of a neuronal axis to mediate the effects of
protein sensing on whole-body glucose homeostasis. Gut-peptides released in
response to luminal nutrients act on locally expressed receptors to stimulate vagal
afferent neuron firing9, and co-infusion of tetracaine, a topical anesthetic, with
intraintestinal nutrients negates the ability of nutrient sensing to suppress food intake
and lower glucose production by blocking afferent neuronal signaling to the brain138,193.
We therefore co-infused tetracaine with upper small intestinal casein hydrolysate during
the IVGTT in a new group of rats, to assess whether a gut-brain neuronal axis is
required for intestinal protein sensing to improve glucose tolerance. Infusion of
tetracaine alone (1 mg/mL, 0.01 mg/min) had no effect on glucose tolerance compared
45
to saline, while co-infusion of tetracaine with 8% casein hydrolysate reversed the
improvement in glucose tolerance by casein hydrolysate (Figure 7A). The integrated
AUC was reversed to that of the saline-treated rats (Figure 7B). Therefore, intestinal
protein activates local, neuronal signaling in order to regulate glucose homeostasis and
improve glucose tolerance, further supporting that the signaling mechanism of protein
sensing is localized within the gut.
46
A B
Figure 3: Gut infusion-IVGTT protocol to evaluate the effects of upper small intestinal protein sensing on glucose tolerance. A, Experimental protocol for the
intravenous glucose tolerance test with upper intestinal infusions. IVGTT, intravenous
glucose tolerance test; SI, small intestine. B, Systemic and portal vein plasma free
amino acid levels in response to the 50-minute upper intestinal saline (n=10) or casein
hydrolysate (n=10) infusion. Values expressed as mean ± SEM. No differences among
groups as determined by unpaired Student’s t-test.
47
A B
Figure 4: Upper small intestinal infusion of protein improves glucose tolerance. A, Plasma glucose concentrations over time during the intravenous glucose tolerance
test in rats receiving an upper small intestinal infusion of saline (n=10) or casein
hydrolysate (n=10). B, The integrated area under the curve (AUC). Values expressed
as mean ± SEM. * p < 0.05, ** p < 0.005 compared to saline as determined by two-way
ANOVA.
48
A B
Figure 5. Upper small intestinal casein hydrolysate increases the glucose infusion rate during the basal insulin euglycemic clamp. A, Experimental protocol
for the basal insulin euglycemic clamp. B, The glucose infusion rate required to
maintain euglycemia during the clamp with upper small intestinal infusion of saline
(n=7) or casein hydrolysate (n=7). Values expressed as mean ± SEM. * P < 0.05
compared to saline as determined by unpaired Student’s t-test.
49
A B
C
m
Figure 6. Upper small intestinal casein hydrolysate suppresses hepatic glucose production. A, B, C, Rate of glucose production (A), suppression of glucose
production expressed as the percent decrease from basal (B) and clamp rate of
glucose uptake (C) with upper small intestinal infusion of saline (n=7) or casein
hydrolysate (n=7). Values expressed as mean ± SEM. * P < 0.05 compared to saline as
determined by unpaired Student’s t-test.
50
A
B
Figure 7: Upper small intestinal protein requires local, neuronal signaling to regulate glucose tolerance. A, Plasma glucose concentrations over time during the
intravenous glucose tolerance test with upper small intestinal infusion of saline (n=10),
casein hydrolysate (n=10), tetracaine (n=8) or casein hydrolysate with tetracaine (n=8).
B, The integrated area under the curve (AUC). Values expressed as mean ± SEM. * P
< 0.05 compared to saline, # P < 0.05 compared to tetracaine, t P < 0.05 compared to
51
casein hydrolysate + tetracaine, as determined by two-way ANOVA and Tukey post
hoc test.
Table 1: Typical amino acid content of Casein enzymatic hydrolysate from Sigma-Aldrich (Product 22090).
Amino acid Typical concentration (%w/w)
Glutamic acid 16.5
Proline 8.5
Leucine 6.5
Lysine 6.4
Aspartic acid 5.5
Valine 5.3
Isoleucine 4.5
Serine 4.5
Phenylalanine 3.8
Threonine 3.6
Arginine 2.9
Alanine 2.4
Methionine 2.4
Histidine 2.1
Tyrosine 1.8
Glycine 1.6
Tryptophan 0.95
Cystine 0.67
52
Table 2: Body weight and cumulative post-surgical food intake of the groups of rats that underwent either the intravenous glucose tolerance test or clamp protocol.
SAL (IVGTT)
CAS (IVGTT)
TET (IVGTT)
CAS + TET
(IVGTT)
SAL (clamp)
CAS (clamp)
Body weight (g) 279 ± 6.0 280 ± 3.9 274 ± 4.9 263 ± 7.9 295 ± 6.7 298 ± 10.4
Food intake (g) 26.1 ± 3.5 23.3 ± 3.2 21 ± 2.9 18 ± 3 30.0 ± 2.9 29.2 ± 2.6
Values expressed as mean ± SEM. Saline (SAL). Casein hydrolysate (CAS).
Tetracaine (TET). Intravenous glucose tolerance test (IVGTT). Basal insulin euglycemic
clamp (clamp).
53
Table 3: Plasma glucose concentrations during the basal insulin euglycemic clamp.
Basal Saline Casein hydrolysate
Glucose (mg/dL) 142.4 ± 6.5 137.8 ± 6.3
Clamp Saline Casein hydrolysate
Glucose (mg/dL) 159.3 ± 5.5 147.2 ± 2.8
Values expressed as mean ± SEM.
54
Chapter 5
Discussion
To date, the role of dietary protein in the regulation of glucose homeostasis remains
unclear. Although there is evidence that the resulting increase in plasma amino acids
may contribute to gluconeogenesis and induce insulin resistance27,194, many studies
show that high-protein diet feeding in fact lowers fasting glucose and HbA1c levels and
improves glucose tolerance28,29,32-34. The mechanisms of this improvement in glucose
control are unknown, but may involve acute negative feedback by intestinal protein
sensing. Indeed, using a model of healthy, male, Sprague-Dawley rats, we here
demonstrate that upper small intestinal protein sensing regulates whole-body glucose
homeostasis. Specifically, a 50-minute upper small intestinal infusion of casein
hydrolysate improved glucose tolerance as assessed by an IVGTT in comparison to
rats given a control infusion of saline, independent of any differences in food intake or
body weight.
Analysis using the ninhydrin method indicated that this improvement in glucose
tolerance occurred independent of a rise in either portal vein or systemic free amino
acid levels. Circulating amino acids can act on other targets to regulate glucose
homeostasis, such as in the hypothalamus to lower hepatic glucose production via a
brain-liver neuronal network195. In addition, vagal afferents innervating the portal vein
respond to portal amino acid infusion196,197, implying the presence of portal amino acid
55
sensors. However, the fact that amino acid levels were not raised by the 50-minute
casein hydrolysate infusion suggests that protein acts via gut-localized sensing
mechanisms to regulate whole-body glucose homeostasis during the IVGTT.
It is, however, important to note that the plasma samples were deproteinized, and the
ninhydrin assay measured only free amino acids, not accounting for those that make up
oligopeptides. It can therefore not be ruled out that di- and tripeptides absorbed by the
gut epithlium intact are reaching the portal vein within 50 minutes. During digestion of a
mixed meal, 90% of oligopeptides absorbed by epithelial cells intact are hydrolyzed
intracellularly and reach the portal vein as free amino acids198. However, given that
apical peptide transporters are upregulated by the presence of luminal oligopeptides199,
our intraintestinal casein hydrolysate infusion may lead to increased flux of peptide
absorption, causing release of excess peptides into the circulation, which are missed
by the ninhydrin assay, and which can act on peripheral targets to regulate glucose
homeostasis. Therefore, future studies should employ a control group where the 8%
casein hydrolysate treatment is infused at the same rate directly into the portal vein
(assuming 100% leakage), to rule out post-absorptive effects improving glucose
tolerance. Nevertheless, the present results suggest that dietary proteins act locally
within the upper small intestine to improve whole-body glucose tolerance in healthy
rodents.
56
These findings are in line with previous studies showing that acute protein intake can
improve glucose tolerance. Consumption of a protein hydrolysate beverage lowers the
glucose response to a subsequent mixed meal43,200, and the addition of protein
hydrolysates to a standard carbohydrate beverage lowers the glucose response42.
Furthermore, consumption of a 5g high-protein diet meal results in a lower glucose
response than a 5g low-protein meal as early as 30 minutes after the initiation of
feeding45. One proposed mechanism of this lowered glucose response is a protein-
induced lowering of gastric emptying rate201, which would then slow the appearance of
glucose into the circulation. However, our current findings indicate that when the
confounding variable of gastric emptying is removed by intravenous injection of the
glucose bolus, intestinal protein signals to improve whole-body glucose tolerance, and
gut protein sensing may therefore contribute to the improvement in glucose response
seen in these acute feeding studies.
The improvement in intravenous glucose tolerance induced by small intestinal protein
sensing must be accounted for by a suppression of endogenous glucose production
and/or increase in peripheral glucose uptake. There are multiple mechanisms through
which gut protein sensing may alter either of these factors. The improvement in glucose
turnover may be secondary to a change in circulating glucoregulatory hormones, given
that protein intake stimulates the release of insulin202, and may do so via pre-absorptive
gut peptide-mediated signaling. GLP-1, which is released in response to luminal
protein, stimulates the release of insulin either via direct action on β-cells or a local
neuronal axis mediated by hepatoportal vagal afferents and pancreatic efferents203, in
57
order to improve glucose tolerance129. Additionally, protein-induced CCK release may
contribute to this incretin effect given that CCK is implicated in stimulating postprandial
insulin secretion both in vitro and in vivo134,204. In many instances, however, acute
protein intake improves glucose homeostasis independently of a rise in insulin
levels43,45. Indeed, protein-induced gut peptide release could regulate glucose
homeostasis independently of insulin, such as via a GLP-1-mediated gut-brain-muscle
neuronal axis to increase muscle uptake and metabolism130,205. However, the most like
likely explanation may be a suppression of hepatic glucose production rather than an
increase in glucose uptake, given that both fatty acid and glucose sensing within the
small intestine suppresses hepatic glucose production via a gut-brain-liver neuronal
axis, independently of any effects on glucose uptake, during a basal insulin pancreatic
clamp13,138.
To investigate whether upper small intestinal protein sensing regulates either glucose
uptake or glucose production, independently of any changes in insulin, the 50-minute
casein hydrolysate infusion was next given during a basal-insulin euglycemic clamp.
During the clamp, upper small intestinal protein infusion increased the glucose infusion
rate required to maintain euglycemic, and this was completely accounted for by a
suppression of hepatic glucose production, and glucose uptake remained unchanged.
Thus, upper small intestinal protein-sensing mechanisms directly regulate hepatic
glucose production, and this likely contributes to the improvement in whole-body
glucose tolerance in response to intestinal protein during the IVGTT. However, the
contribution of this suppression of hepatic glucose production to the improvement in
58
glucose tolerance seen during the IVGTT remains unknown. In order to address the
contribution of hepatic glucose metabolism in future experiments, metabolic pathways
regulating glucose production in the liver could be blocked during the IVGTT.
Upper small intestinal lipids initiate a gut-brain-liver neuronal axis, mediated by vagal
afferents, NMDA receptor transmission in the DVC and the hepatic vagal efferent to
suppress hepatic glucose production138. Thus, a similar neuronal axis may mediate
intestinal protein to suppress glucose production. Indeed, co-infusion of the local
anesthetic tetracaine completely reversed the improvement in glucose tolerance by
upper intestinal protein infusion, indicating that pre-absorptive protein initiates a
neuronal network at the level of the gut to exert its effects on glucose homeostasis.
Alternatively, upper small intestinal infusion of tetracaine alone did not affect glucose
homeostasis during the IVGTT, indicating that the contribution of basal vagal afferent
firing to glucoregulatory control is negligible, whereas a postprandial increase in firing is
required for nutrients to regulate glucose homeostasis. These findings are consistent
with a recent study investigating the role of gut neuronal signaling in humans. When
implanted in the stomach, the electrical DIAMOND® device senses incoming food and
responds with electrical stimulation of the gut wall. After 5 weeks, this postprandial
neuronal stimulation resulted in an improvement in glycemic control (lower HbA1c) in
type 2 diabetic individuals206. Thus, the present findings are likely to be conserved in
humans and may be important in the context of disease.
59
Future studies are required to dissect the involvement of a gut-brain or gut-brain-liver
neuronal axis in the regulation of glucose tolerance and glucose production. The ability
of upper small intestinal lipids to suppress hepatic glucose production is attenuated not
only by co-infusion of tetracaine but also by blocking NMDA receptor transmission
within the NTS of the hindbrain or by surgical ablation of the hepatic vagal efferent,
implicating a gut-brain-liver axis mediated by vagal afferents, NMDA transmission in the
NTS and the hepatic vagus138. Pharmacological inhibition of NTS NMDA receptors, by
NTS infusion of the noncompetitive high-affinity antagonist MK-801, and hepatic
vagotomy surgery should thus be utilized during future studies to investigate whether a
similar gut-brain-liver axis mediates intestinal protein to suppress hepatic glucose
production during the pancreatic clamp.
The precise mechanisms through which upper small intestinal casein hydrolysate
initiates a neuronal network regulating glucose homeostasis remain unknown. Casein
hydrolysate is a partially hydrolyzed form of protein, containing both individual amino
acids and oligopeptides, for both of which there are sensory machineries expressed by
GI epithelial cells that are implicated in gut peptide release. A number of amino acid-
specific GPCRs are expressed by EECs and mediate CCK release in response to
amino acids in vitro56,168,172,173, which vary in their affinity for different classes of amino
acids. Casein hydrolysate is composed of a broad range of amino acids, with the
highest proportion being Glutamic acid followed by the aliphatic amino acids Proline,
Leucine and Lysine. Indeed, the gut epithelium expresses glutamate receptors, which
mediate gut peptide release and vagal afferent firing in response to luminal glutamate
60
infusion and possibly to high protein meals207, one of which is T1R1-T1R3, the gut-
expressed α–gustducin coupled GPCR and “umami” taste receptor168. The role of
aliphatic amino acids such as Leucine in the gut-brain axis is less clear given that
although intraduodenal infusion of protein hydrolysate suppresses feeding, infusion of
Leucine, Arginine or Alanine independently does not suppress feeding162. Alternatively,
infusion of the aromatic amino acids Phenylalanine or Tryptophan alone suppresses
feeding162. Indeed, Phenylalanine and Tryptophan stimulate CCK release and suppress
feeding via a vagal afferent-dependent neural axis in both rodents and humans161,208,
and Phenylalanine infusion is in fact more potent than casein hydrolysate to suppress
feeding in rodents92. These findings indicate that although Tryptophan and
Phenylalanine are in lower proportion than other amino acids in casein hydrolysate,
they may be the signaling molecules through which this protein solution initiates a gut-
brain axis. Future studies should look at whether infusion of either of aromatic amino
acids alone can equally or more potently regulate glucose tolerance and glucose
production in comparison to the casein treatment. In vitro, aromatic amino acids are
sensed by the GPCR CaSR, which is expressed by EECs, in order to stimulate CCK
release56, thus the role of this transporter in protein-induced glucoregulation should
also be investigated. Alternatively, uptake and metabolism of amino acids by gut
epithelial cells may be required, as in the case of intestinal lipid sensing, where
metabolism to LCFA-CoA is required for lipids to stimulate CCK release and lower
glucose production138. Indeed, hypothalamic leucine infusion lowers plasma glucose via
a suppression of hepatic glucose production, and this is dependent upon metabolism to
the intermediate α-ketoisocaproic acid and subsequently to acetyl-coA and malonyl-
CoA195, which is known to increase cytoplasmic accumulation of LCFA-CoA, increasing
61
flux into the lipid sensing pathway to suppress glucose production. Given that upper
intestinal accumulation of LCFA-CoA activates a CCK-dependent gut-brain-liver axis to
suppress glucose production138, intestinal amino acids may act through a similar
pathway to regulate glucose homeostasis via metabolism to malonyl-CoA.
However, protein hydrolysates or solutions of small peptides are more efficiently
absorbed than amino acid mixtures, suggesting that a large amount of dietary protein is
absorbed in the form of oligopeptides rather than hydrolyzed into amino acids within the
lumen. Therefore, luminal protein hydrolysate may additionally or alternatively signal in
the form of oligopeptides. Indeed, co-infusion of the proteolytic enzyme trypsin
attenuates the CCK response to luminal protein hydrolysate182, and non-metabolizable
oligopeptides stimulate CCK release183. The protein-sensor PepT1 is likely involved in
sensing these oligopeptides, given that this di- and tripeptide-specific transporter
mediates CCK release as well as vagal afferent firing in response to intestinal protein
hydrolysate58,181. In order to evaluate the role of PepT1, future studies will employ co-
infusion of the competitive non-translocated inhibitor 4-aminomethylbenzoic acid (4-
AMBA) with upper small intestinal protein during both the IVGTT and clamp protocols.
To further confirm the role of PepT1, the PepT1 protein will be knocked down in the
upper small intestine with a lentiviral shRNA infection during the gut cannulation
surgery as confirmed in Côté et al209. Finally, upper small intestinal infusion with non-
metabolizable substrates of PepT1 such as the cephalosporin antibiotic Cefaclor or the
synthetic dipeptide Gly-Sar during the IVGTT or clamp would confirm whether substrate
binding and activation of PepT1 per se initiates the neuronal network to regulate
62
glucose homeostasis or whether subsequent intracellular metabolism of peptides is
required.
Identification of the precise mechanisms through which protein initiates this negative
feedback pathway on glucose metabolism is important to potentially unveil therapeutic
targets at the level of the gut to lower hyperglycemia in disease. Indeed, this gut-brain-
liver axis has recently been demonstrated to have important therapeutic relevance.
Both metformin and resveratrol activate gut-localized signaling pathways to lower
hepatic glucose production via a neuronal gut-brain-liver axis in high-fat diet-fed and
type 2 diabetic rodents10,209. Furthermore, in humans, 12-week treatment with delayed-
release Metformin, which targets the lower bowel where little absorption occurs, is
more effective in lowering glucose levels in type 2 diabetic patients than 12 weeks of
commercially available immediate-release or extended-release Metformin11. These
results confirm those in rodents suggesting that the primary effect of Metformin on
glucose homeostasis may be via gut-localized signaling. These exciting new studies
confirm that gut nutrient signaling pathways may have pharmacological relevance in
disease and that it is urgent to elucidate the precise molecular mechanisms through
which intestinal nutrients signal, and how signaling defects in high-fat feeding may be
bypassed by selectively targeting these pathways.
While we have confirmed that upper small intestinal protein sensing regulates
intravenous glucose tolerance and suppresses glucose production during the
63
pancreatic clamp, future studies are required to determine the physiological relevance
of protein sensing in the context of high-protein feeding. As previously mentioned, re-
feeding of a high-protein diet following an overnight fast lowers the glucose response in
healthy male Sprague-Dawley rats in comparison to low-protein feeding45.
Interestingly, blocking hindbrain glucagon receptor signaling partially attenuates this
improvement in glucose tolerance in the later time points (60 minutes after re-
feeding)45, but has no effect on the earlier time points. Thus, the same fasting re-
feeding protocol should be employed in future studies to investigate the role of
intestinal protein sensing in mediating this early improvement in glucose control. Once
we have identified the specific mucosal sensing mechanisms that mediate protein to
improve glucose homeostasis, using the techniques described above, this pathway
should be blocked during re-feeding of a high-protein diet through pharmacological
inhibition or viral knockdown. To investigate how intestinal protein sensing might
contribute to the glucoregulatory capacity of longer-term dietary interventions, knockout
mouse models could be employed. For example, PepT1 mice that lack the transporter
in the intestines and kidney have been developed, and do not display any obvious
abnormalities in size, weight fertility or viability210. It would be interesting to investigate
whether the lack of intestinal PepT1 might become important in the context of high
protein diet feeding, whereby PepT1 knockout attenuates the ability of long-term high
protein diet intervention to improve glucose regulation.
In summary, the present study shows for the first time to our knowledge that upper
small intestinal protein initiates a neuronal network to improve glucose tolerance and
64
suppress hepatic glucose production, likely via pre-absorptive signaling to initiate gut-
brain and/or gut-brain liver signaling axes. These findings demonstrate that the GI tract
and brain have parallel protein-sensing mechanisms to lower hepatic glucose
production given that central amino acid infusion lowers glucose production during the
same basal insulin pancreatic clamp protocol195,211. While blocking neuronal signaling
with tetracaine completely reversed the effects of intraintestinal protein infusion on
glucose tolerance in the context of a dose which does not rise portal or systemic
plasma amino acids, it is important to note that under physiological high-protein feeding
conditions, where amino acids rise in the circulation, other protein-sensing mechanisms
such as in the brain likely become important.
It will be of great interest in future studies to test the efficacy of upper small intestinal
protein infusion to regulate glucose homeostasis in high-fat diet-fed rats. 3 days of
high-fat diet feeding reverses the effects of upper small intestinal lipid infusion to lower
glucose production, by disrupting the lipid-sensing pathway at the level of intestinal
CCK-1 receptor signaling138,143. Interestingly, however, high protein diet feeding
effectively improves glucose homeostasis in diet-induced obese rodents212,213, and
acute protein intake lowers blood glucose levels in type 2 diabetic humans214,215,216.
Thus, we propose that unlike lipid sensing, intestinal protein sensing mechanisms may
in fact remain intact in rodent models of metabolic disease, suggesting that protein-
sensing pathways may differ from lipid sensing, and further justifying the importance to
investigate the potential therapeutic relevance.
65
Chapter 6
References
1 Scully, T. Diabetes in numbers. Nature 485, S2-‐3 (2012). 2 Speakman, J. R. & O'Rahilly, S. Fat: an evolving issue. Dis Model Mech 5, 569-‐573,
doi:10.1242/dmm.010553 (2012). 3 Association, C. D. Diabetes Statistics in Canada, <http://www.diabetes.ca/how-you-can-
help/advocate/why-federal-leadership-is-essential/diabetes-statistics-in-canada - _ftn1> (2016).
4 Canada, P. H. A. o. Obesity in Canada, <http://www.phac-aspc.gc.ca/hp-ps/hl-mvs/oic-oac/index-eng.php> (2011).
5 Stagnitti, M. N. & Medical Expenditure Panel Survey (U.S.). in Statistical brief ; #34 [5] p. (Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality, [Rockville, Md., 2004).
6 Scheen, A. J. Pathophysiology of type 2 diabetes. Acta Clin Belg 58, 335-‐341, doi:10.1179/acb.2003.58.6.001 (2003).
7 Best, J. D. et al. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19, 1018-‐1030 (1996).
8 Schwartz, M. W. et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 503, 59-‐66, doi:10.1038/nature12709 (2013).
9 Hamr, S. C., Wang, B., Swartz, T. D. & Duca, F. A. Does nutrient sensing determine how we "see" food? Curr Diab Rep 15, 604, doi:10.1007/s11892-‐015-‐0604-‐7 (2015).
10 Duca, F. A. et al. Metformin activates a duodenal Ampk-‐dependent pathway to lower hepatic glucose production in rats. Nat Med 21, 506-‐511, doi:10.1038/nm.3787 (2015).
11 Buse, J. B. et al. The Primary Glucose-‐Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-‐term Pharmacokinetic and 12-‐Week Dose-‐Ranging Studies. Diabetes Care 39, 198-‐205, doi:10.2337/dc15-‐0488 (2016).
12 Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366, 1567-‐1576, doi:10.1056/NEJMoa1200225 (2012).
13 Breen, D. M. et al. Jejunal nutrient sensing is required for duodenal-‐jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 18, 950-‐955, doi:10.1038/nm.2745 (2012).
14 Lovshin, J. A. & Drucker, D. J. Incretin-‐based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5, 262-‐269, doi:10.1038/nrendo.2009.48 (2009).
15 Tessari, P. et al. Hyperaminoacidaemia reduces insulin-‐mediated glucose disposal in healthy man. Diabetologia 28, 870-‐872 (1985).
16 Buckspan, R. et al. alpha-‐Ketoisocaproate is superior to leucine in sparing glucose utilization in humans. Am J Physiol 251, E648-‐653 (1986).
66
17 Flakoll, P. J., Wentzel, L. S., Rice, D. E., Hill, J. O. & Abumrad, N. N. Short-‐term regulation of insulin-‐mediated glucose utilization in four-‐day fasted human volunteers: role of amino acid availability. Diabetologia 35, 357-‐366 (1992).
18 Pisters, P. W., Restifo, N. P., Cersosimo, E. & Brennan, M. F. The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. Metabolism: Clinical & Experimental 40, 59-‐65 (1991).
19 Krebs, M. et al. Mechanism of amino acid-‐induced skeletal muscle insulin resistance in humans. Diabetes 51, 599-‐605 (2002).
20 Traxinger, R. R. & Marshall, S. Role of amino acids in modulating glucose-‐induced desensitization of the glucose transport system. J Biol Chem 264, 20910-‐20916 (1989).
21 Walajtys-‐Rode, E. & Williamson, J. R. Effects of branched chain alpha-‐ketoacids on the metabolism of isolated rat liver cells. III. Interactions with pyruvate dehydrogenase. J Biol Chem 255, 413-‐418 (1980).
22 Chang, T. W. & Goldberg, A. L. Leucine inhibits oxidation of glucose and pyruvate in skeletal muscles during fasting. J Biol Chem 253, 3696-‐3701 (1978).
23 Tremblay, F. & Marette, A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276, 38052-‐38060, doi:10.1074/jbc.M106703200 (2001).
24 Patti, M. E., Brambilla, E., Luzi, L., Landaker, E. J. & Kahn, C. R. Bidirectional modulation of insulin action by amino acids. J Clin Invest 101, 1519-‐1529, doi:10.1172/JCI1326 (1998).
25 Boden, G. & Tappy, L. Effects of amino acids on glucose disposal. Diabetes 39, 1079-‐1084 (1990).
26 Tappy, L. et al. Effects of infused amino acids on glucose production and utilization in healthy human subjects. Am J Physiol 262, E826-‐833 (1992).
27 Rossetti, L., Rothman, D. L., DeFronzo, R. A. & Shulman, G. I. Effect of dietary protein on in vivo insulin action and liver glycogen repletion. Am J Physiol 257, E212-‐219 (1989).
28 Foster, G. D. et al. A randomized trial of a low-‐carbohydrate diet for obesity. N Engl J Med 348, 2082-‐2090, doi:10.1056/NEJMoa022207 (2003).
29 Samaha, F. F. et al. A low-‐carbohydrate as compared with a low-‐fat diet in severe obesity. N Engl J Med 348, 2074-‐2081, doi:10.1056/NEJMoa022637 (2003).
30 Skov, A. R., Toubro, S., Ronn, B., Holm, L. & Astrup, A. Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. International Journal of Obesity & Related Metabolic Disorders 23, 528-‐536 (1999).
31 Pichon, L., Huneau, J. F., Fromentin, G. & Tome, D. A high-‐protein, high-‐fat, carbohydrate-‐free diet reduces energy intake, hepatic lipogenesis, and adiposity in rats. J Nutr 136, 1256-‐1260 (2006).
32 Arciero, P. J. et al. Moderate protein intake improves total and regional body composition and insulin sensitivity in overweight adults. Metabolism: Clinical & Experimental 57, 757-‐765, doi:10.1016/j.metabol.2008.01.015 (2008).
33 Boden, G., Sargrad, K., Homko, C., Mozzoli, M. & Stein, T. P. Effect of a low-‐carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 142, 403-‐411 (2005).
67
34 Stern, L. et al. The effects of low-‐carbohydrate versus conventional weight loss diets in severely obese adults: one-‐year follow-‐up of a randomized trial. Ann Intern Med 140, 778-‐785 (2004).
35 Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34, 1481-‐1486, doi:10.2337/dc10-‐2415 (2011).
36 Gannon, M. C., Nuttall, F. Q., Saeed, A., Jordan, K. & Hoover, H. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 78, 734-‐741 (2003).
37 Nagata, C. et al. Branched-‐chain amino acid intake and the risk of diabetes in a Japanese community: the Takayama study. Am J Epidemiol 178, 1226-‐1232, doi:10.1093/aje/kwt112 (2013).
38 Lacroix, M. et al. A long-‐term high-‐protein diet markedly reduces adipose tissue without major side effects in Wistar male rats. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 287, R934-‐942, doi:10.1152/ajpregu.00100.2004 (2004).
39 Faipoux, R. et al. Yeast proteins enhance satiety in rats. J Nutr 136, 2350-‐2356 (2006).
40 Blouet, C. et al. The reduced energy intake of rats fed a high-‐protein low-‐carbohydrate diet explains the lower fat deposition, but macronutrient substitution accounts for the improved glycemic control. J Nutr 136, 1849-‐1854 (2006).
41 Gannon, M. C. & Nuttall, F. Q. Acute effects of ingestion of carbohydrate, protein, or fat on cardiac glycogen metabolism in rats. Metabolism: Clinical & Experimental 36, 595-‐600 (1987).
42 Claessens, M., Calame, W., Siemensma, A. D., van Baak, M. A. & Saris, W. H. The effect of different protein hydrolysate/carbohydrate mixtures on postprandial glucagon and insulin responses in healthy subjects. Eur J Clin Nutr 63, 48-‐56, doi:10.1038/sj.ejcn.1602896 (2009).
43 Akhavan, T., Luhovyy, B. L., Brown, P. H., Cho, C. E. & Anderson, G. H. Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults. Am J Clin Nutr 91, 966-‐975, doi:10.3945/ajcn.2009.28406 (2010).
44 Gunnerud, U. J., Heinzle, C., Holst, J. J., Ostman, E. M. & Bjorck, I. M. Effects of pre-‐meal drinks with protein and amino acids on glycemic and metabolic responses at a subsequent composite meal. PLoS One 7, e44731, doi:10.1371/journal.pone.0044731 (2012).
45 LaPierre, M. P., Abraham, M. A., Yue, J. T., Filippi, B. M. & Lam, T. K. Glucagon signalling in the dorsal vagal complex is sufficient and necessary for high-‐protein feeding to regulate glucose homeostasis in vivo. EMBO Rep 16, 1299-‐1307, doi:10.15252/embr.201540492 (2015).
46 Day, J. L. et al. Factors governing insulin and glucagon responses during normal meals. Clin Endocrinol (Oxf) 9, 443-‐454 (1978).
47 Mighiu, P. I. et al. Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med 19, 766-‐772, doi:10.1038/nm.3115 (2013).
48 Ritter, R. C. Gastrointestinal mechanisms of satiation for food. Physiology & Behavior 81, 249-‐273, doi:10.1016/j.physbeh.2004.02.012 (2004).
68
49 Tolhurst, G., Reimann, F. & Gribble, F. M. Intestinal sensing of nutrients. Handb Exp Pharmacol, 309-‐335, doi:10.1007/978-‐3-‐642-‐24716-‐3_14 (2012).
50 Habib, A. M. et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153, 3054-‐3065, doi:10.1210/en.2011-‐2170 (2012).
51 Svendsen, B. et al. An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology 156, 847-‐857, doi:10.1210/en.2014-‐1710 (2015).
52 Svendsen, B. et al. GLP1-‐ and GIP-‐producing cells rarely overlap and differ by bombesin receptor-‐2 expression and responsiveness. J Endocrinol 228, 39-‐48, doi:10.1530/JOE-‐15-‐0247 (2016).
53 Edfalk, S., Steneberg, P. & Edlund, H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57, 2280-‐2287, doi:10.2337/db08-‐0307 (2008).
54 Little, T. J. et al. Characterization of duodenal expression and localization of fatty acid-‐sensing receptors in humans: relationships with body mass index. American Journal of Physiology: Gastrointestinal & Liver Physiology 307, G958-‐967, doi:10.1152/ajpgi.00134.2014 (2014).
55 Iwasaki, K. et al. Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion. Endocrinology 156, 837-‐846, doi:10.1210/en.2014-‐1653 (2015).
56 Liou, A. P. et al. The extracellular calcium-‐sensing receptor is required for cholecystokinin secretion in response to L-‐phenylalanine in acutely isolated intestinal I cells. American Journal of Physiology: Gastrointestinal & Liver Physiology 300, G538-‐546, doi:10.1152/ajpgi.00342.2010 (2011).
57 Reimann, F. et al. Glucose sensing in L cells: a primary cell study. Cell Metab 8, 532-‐539, doi:10.1016/j.cmet.2008.11.002 (2008).
58 Liou, A. P. et al. Protein hydrolysate-‐induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1. American Journal of Physiology: Gastrointestinal & Liver Physiology 300, G895-‐902, doi:10.1152/ajpgi.00521.2010 (2011).
59 Psichas, A., Reimann, F. & Gribble, F. M. Gut chemosensing mechanisms. J Clin Invest 125, 908-‐917, doi:10.1172/JCI76309 (2015).
60 Parker, H. E. et al. Predominant role of active versus facilitative glucose transport for glucagon-‐like peptide-‐1 secretion. Diabetologia 55, 2445-‐2455, doi:10.1007/s00125-‐012-‐2585-‐2 (2012).
61 Gorboulev, V. et al. Na(+)-‐D-‐glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-‐dependent incretin secretion. Diabetes 61, 187-‐196, doi:10.2337/db11-‐1029 (2012).
62 Geraedts, M. C. et al. Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery. American Journal of Physiology: Endocrinology & Metabolism 303, E464-‐474, doi:10.1152/ajpendo.00163.2012 (2012).
63 Liou, A. P. et al. The G-‐protein-‐coupled receptor GPR40 directly mediates long-‐chain fatty acid-‐induced secretion of cholecystokinin. Gastroenterology 140, 903-‐912, doi:10.1053/j.gastro.2010.10.012 (2011).
69
64 Lu, W. J. et al. Chylomicron formation and secretion is required for lipid-‐stimulated release of incretins GLP-‐1 and GIP. Lipids 47, 571-‐580, doi:10.1007/s11745-‐011-‐3650-‐1 (2012).
65 Whited, K. L., Lu, D., Tso, P., Kent Lloyd, K. C. & Raybould, H. E. Apolipoprotein A-‐IV is involved in detection of lipid in the rat intestine. J Physiol 569, 949-‐958, doi:10.1113/jphysiol.2005.097634 (2005).
66 Lo, C. C. et al. Apolipoprotein AIV requires cholecystokinin and vagal nerves to suppress food intake. Endocrinology 153, 5857-‐5865, doi:10.1210/en.2012-‐1427 (2012).
67 Brighton, C. A. et al. Bile Acids Trigger GLP-‐1 Release Predominantly by Accessing Basolaterally Located G Protein-‐Coupled Bile Acid Receptors. Endocrinology 156, 3961-‐3970, doi:10.1210/en.2015-‐1321 (2015).
68 Trabelsi, M. S. et al. Farnesoid X receptor inhibits glucagon-‐like peptide-‐1 production by enteroendocrine L cells. Nat Commun 6, 7629, doi:10.1038/ncomms8629 (2015).
69 Koide, M., Okabayashi, Y. & Otsuki, M. Role of endogenous bile on basal and postprandial CCK release in humans. Digestive Diseases & Sciences 38, 1284-‐1290 (1993).
70 Brenner, L., Yox, D. P. & Ritter, R. C. Suppression of sham feeding by intraintestinal nutrients is not correlated with plasma cholecystokinin elevation. Am J Physiol 264, R972-‐976 (1993).
71 Lo, C. C. et al. Intraperitoneal CCK and fourth-‐intraventricular Apo AIV require both peripheral and NTS CCK1R to reduce food intake in male rats. Endocrinology 155, 1700-‐1707, doi:10.1210/en.2013-‐1846 (2014).
72 Larsen, P. J., Tang-‐Christensen, M., Holst, J. J. & Orskov, C. Distribution of glucagon-‐like peptide-‐1 and other preproglucagon-‐derived peptides in the rat hypothalamus and brainstem. Neuroscience 77, 257-‐270 (1997).
73 Campos, R. V., Lee, Y. C. & Drucker, D. J. Divergent tissue-‐specific and developmental expression of receptors for glucagon and glucagon-‐like peptide-‐1 in the mouse. Endocrinology 134, 2156-‐2164, doi:10.1210/endo.134.5.8156917 (1994).
74 Holst, J. J. The physiology of glucagon-‐like peptide 1. Physiol Rev 87, 1409-‐1439, doi:10.1152/physrev.00034.2006 (2007).
75 D'Alessio, D. et al. Fasting and postprandial concentrations of GLP-‐1 in intestinal lymph and portal plasma: evidence for selective release of GLP-‐1 in the lymph system. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 293, R2163-‐2169, doi:10.1152/ajpregu.00911.2006 (2007).
76 Ohlsson, L., Kohan, A. B., Tso, P. & Ahren, B. GLP-‐1 released to the mesenteric lymph duct in mice: effects of glucose and fat. Regul Pept 189, 40-‐45, doi:10.1016/j.regpep.2014.02.001 (2014).
77 Kohan, A., Yoder, S. & Tso, P. Lymphatics in intestinal transport of nutrients and gastrointestinal hormones. Ann N Y Acad Sci 1207 Suppl 1, E44-‐51, doi:10.1111/j.1749-‐6632.2010.05753.x (2010).
78 Batterham, R. L. et al. Gut hormone PYY(3-‐36) physiologically inhibits food intake. Nature 418, 650-‐654, doi:10.1038/nature02666 (2002).
79 Berthoud, H. R. Anatomical demonstration of vagal input to nicotinamide acetamide dinucleotide phosphate diaphorase-‐positive (nitrergic) neurons in rat fundic stomach. J Comp Neurol 358, 428-‐439, doi:10.1002/cne.903580309 (1995).
70
80 Prechtl, J. C. & Powley, T. L. The fiber composition of the abdominal vagus of the rat. Anatomy & Embryology 181, 101-‐115 (1990).
81 Dockray, G. J. Enteroendocrine cell signalling via the vagus nerve. Curr Opin Pharmacol 13, 954-‐958, doi:10.1016/j.coph.2013.09.007 (2013).
82 Amato, A. et al. Peripheral motor action of glucagon-‐like peptide-‐1 through enteric neuronal receptors. Neurogastroenterology & Motility 22, 664-‐e203, doi:10.1111/j.1365-‐2982.2010.01476.x (2010).
83 Patterson, L. M., Zheng, H. & Berthoud, H. R. Vagal afferents innervating the gastrointestinal tract and CCKA-‐receptor immunoreactivity. Anat Rec 266, 10-‐20 (2002).
84 Ritter, R. C. A tale of two endings: modulation of satiation by NMDA receptors on or near central and peripheral vagal afferent terminals. Physiology & Behavior 105, 94-‐99, doi:10.1016/j.physbeh.2011.02.042 (2011).
85 Darling, R. A. et al. Mercaptoacetate and fatty acids exert direct and antagonistic effects on nodose neurons via GPR40 fatty acid receptors. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 307, R35-‐43, doi:10.1152/ajpregu.00536.2013 (2014).
86 Norgren, R. Projections from the nucleus of the solitary tract in the rat. Neuroscience 3, 207-‐218 (1978).
87 Zittel, T. T., De Giorgio, R., Sternini, C. & Raybould, H. E. Fos protein expression in the nucleus of the solitary tract in response to intestinal nutrients in awake rats. Brain Res 663, 266-‐270 (1994).
88 Cote, C. D., Zadeh-‐Tahmasebi, M., Rasmussen, B. A., Duca, F. A. & Lam, T. K. Hormonal signaling in the gut. J Biol Chem 289, 11642-‐11649, doi:10.1074/jbc.O114.556068 (2014).
89 Davis, J. D. & Smith, G. P. Learning to sham feed: behavioral adjustments to loss of physiological postingestional stimuli. Am J Physiol 259, R1228-‐1235 (1990).
90 Gibbs, J., Maddison, S. P. & Rolls, E. T. Satiety role of the small intestine examined in sham-‐feeding rhesus monkeys. Journal of Comparative & Physiological Psychology 95, 1003-‐1015 (1981).
91 Burton-‐Freeman, B., Gietzen, D. W. & Schneeman, B. O. Meal pattern analysis to investigate the satiating potential of fat, carbohydrate, and protein in rats. Am J Physiol 273, R1916-‐1922 (1997).
92 Yox, D. P. & Ritter, R. C. Capsaicin attenuates suppression of sham feeding induced by intestinal nutrients. Am J Physiol 255, R569-‐574 (1988).
93 Yox, D. P., Stokesberry, H. & Ritter, R. C. Vagotomy attenuates suppression of sham feeding induced by intestinal nutrients. Am J Physiol 260, R503-‐508 (1991).
94 Yox, D. P., Stokesberry, H. & Ritter, R. C. Fourth ventricular capsaicin attenuates suppression of sham feeding induced by intestinal nutrients. Am J Physiol 260, R681-‐687 (1991).
95 Gibbs, J., Young, R. C. & Smith, G. P. Cholecystokinin decreases food intake in rats. Journal of Comparative & Physiological Psychology 84, 488-‐495 (1973).
96 Kissileff, H. R., Pi-‐Sunyer, F. X., Thornton, J. & Smith, G. P. C-‐terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34, 154-‐160 (1981).
97 Beglinger, C., Degen, L., Matzinger, D., D'Amato, M. & Drewe, J. Loxiglumide, a CCK-‐A receptor antagonist, stimulates calorie intake and hunger feelings in humans.
71
American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 280, R1149-‐1154 (2001).
98 Matzinger, D. et al. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. Am J Physiol 277, R1718-‐1724 (1999).
99 Lal, S., Kirkup, A. J., Brunsden, A. M., Thompson, D. G. & Grundy, D. Vagal afferent responses to fatty acids of different chain length in the rat. American Journal of Physiology: Gastrointestinal & Liver Physiology 281, G907-‐915 (2001).
100 Brenner, L. A. & Ritter, R. C. Type A CCK receptors mediate satiety effects of intestinal nutrients. Pharmacology, Biochemistry & Behavior 54, 625-‐631 (1996).
101 Covasa, M. & Ritter, R. C. Attenuated satiation response to intestinal nutrients in rats that do not express CCK-‐A receptors. Peptides 22, 1339-‐1348 (2001).
102 Rinaman, L. Hindbrain noradrenergic lesions attenuate anorexia and alter central cFos expression in rats after gastric viscerosensory stimulation. J Neurosci 23, 10084-‐10092 (2003).
103 Beinfeld, M. C. An introduction to neuronal cholecystokinin. Peptides 22, 1197-‐1200 (2001).
104 Moran, T. H., Ameglio, P. J., Schwartz, G. J. & McHugh, P. R. Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am J Physiol 262, R46-‐50 (1992).
105 Broberger, C., Holmberg, K., Shi, T. J., Dockray, G. & Hokfelt, T. Expression and regulation of cholecystokinin and cholecystokinin receptors in rat nodose and dorsal root ganglia. Brain Res 903, 128-‐140 (2001).
106 Blevins, J. E., Stanley, B. G. & Reidelberger, R. D. Brain regions where cholecystokinin suppresses feeding in rats. Brain Res 860, 1-‐10 (2000).
107 Brenner, L. A. & Ritter, R. C. Intracerebroventricular cholecystokinin A-‐receptor antagonist does not reduce satiation by endogenous CCK. Physiology & Behavior 63, 711-‐716 (1998).
108 Lavin, J. H. et al. Interaction of insulin, glucagon-‐like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate. Am J Clin Nutr 68, 591-‐598 (1998).
109 Abbott, C. R. et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-‐36) on food intake. Brain Res 1043, 139-‐144, doi:10.1016/j.brainres.2005.02.065 (2005).
110 Hayes, M. R. et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-‐like-‐peptide-‐1. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 301, R1479-‐1485, doi:10.1152/ajpregu.00356.2011 (2011).
111 Verdich, C. et al. A meta-‐analysis of the effect of glucagon-‐like peptide-‐1 (7-‐36) amide on ad libitum energy intake in humans. Journal of Clinical Endocrinology & Metabolism 86, 4382-‐4389, doi:10.1210/jcem.86.9.7877 (2001).
112 Plamboeck, A. et al. The effect of exogenous GLP-‐1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American Journal of Physiology: Gastrointestinal & Liver Physiology 304, G1117-‐1127, doi:10.1152/ajpgi.00035.2013 (2013).
113 Wright, J. et al. Reduction of food intake by cholecystokinin requires activation of hindbrain NMDA-‐type glutamate receptors. American Journal of Physiology:
72
Regulatory, Integrative & Comparative Physiology 301, R448-‐455, doi:10.1152/ajpregu.00026.2011 (2011).
114 Campos, C. A., Wright, J. S., Czaja, K. & Ritter, R. C. CCK-‐induced reduction of food intake and hindbrain MAPK signaling are mediated by NMDA receptor activation. Endocrinology 153, 2633-‐2646, doi:10.1210/en.2012-‐1025 (2012).
115 Campos, C. A., Shiina, H., Silvas, M., Page, S. & Ritter, R. C. Vagal afferent NMDA receptors modulate CCK-‐induced reduction of food intake through synapsin I phosphorylation in adult male rats. Endocrinology 154, 2613-‐2625, doi:10.1210/en.2013-‐1062 (2013).
116 Babic, T. et al. Phenotype of neurons in the nucleus of the solitary tract that express CCK-‐induced activation of the ERK signaling pathway. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 296, R845-‐854, doi:10.1152/ajpregu.90531.2008 (2009).
117 Sutton, G. M., Duos, B., Patterson, L. M. & Berthoud, H. R. Melanocortinergic modulation of cholecystokinin-‐induced suppression of feeding through extracellular signal-‐regulated kinase signaling in rat solitary nucleus. Endocrinology 146, 3739-‐3747, doi:10.1210/en.2005-‐0562 (2005).
118 Seeley, R. J., Grill, H. J. & Kaplan, J. M. Neurological dissociation of gastrointestinal and metabolic contributions to meal size control. Behav Neurosci 108, 347-‐352 (1994).
119 Moran, T. H. & Bi, S. Hyperphagia and obesity in OLETF rats lacking CCK-‐1 receptors. Philos Trans R Soc Lond B Biol Sci 361, 1211-‐1218, doi:10.1098/rstb.2006.1857 (2006).
120 Elrick, H., Stimmler, L., Hlad, C. J., Jr. & Arai, Y. Plasma Insulin Response to Oral and Intravenous Glucose Administration. Journal of Clinical Endocrinology & Metabolism 24, 1076-‐1082, doi:10.1210/jcem-‐24-‐10-‐1076 (1964).
121 Moens, K. et al. Expression and functional activity of glucagon, glucagon-‐like peptide I, and glucose-‐dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45, 257-‐261 (1996).
122 Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-‐like peptide-‐1 7-‐36: a physiological incretin in man. Lancet 2, 1300-‐1304 (1987).
123 Brown, J. C., Dryburgh, J. R., Ross, S. A. & Dupre, J. Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31, 487-‐532 (1975).
124 D'Alessio, D. A., Kahn, S. E., Leusner, C. R. & Ensinck, J. W. Glucagon-‐like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-‐independent glucose disposal. J Clin Invest 93, 2263-‐2266, doi:10.1172/JCI117225 (1994).
125 Prigeon, R. L., Quddusi, S., Paty, B. & D'Alessio, D. A. Suppression of glucose production by GLP-‐1 independent of islet hormones: a novel extrapancreatic effect. American Journal of Physiology: Endocrinology & Metabolism 285, E701-‐707, doi:10.1152/ajpendo.00024.2003 (2003).
126 Knauf, C. et al. Brain glucagon-‐like peptide-‐1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115, 3554-‐3563, doi:10.1172/JCI25764 (2005).
127 Sandoval, D. A., Bagnol, D., Woods, S. C., D'Alessio, D. A. & Seeley, R. J. Arcuate glucagon-‐like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57, 2046-‐2054, doi:10.2337/db07-‐1824 (2008).
73
128 Krieger, J. P. et al. Knockdown of GLP-‐1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. Diabetes 65, 34-‐43, doi:10.2337/db15-‐0973 (2016).
129 Waget, A. et al. Physiological and pharmacological mechanisms through which the DPP-‐4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152, 3018-‐3029, doi:10.1210/en.2011-‐0286 (2011).
130 Burcelin, R., Da Costa, A., Drucker, D. & Thorens, B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-‐like peptide-‐1 receptor. Diabetes 50, 1720-‐1728 (2001).
131 Balkan, B., Steffens, A. B., Strubbe, J. H. & Bruggink, J. E. Biphasic insulin secretion after intravenous but not after intraportal CCK-‐8 infusion in rats. Diabetes 39, 702-‐706 (1990).
132 Sakamoto, C., Goldfine, I. D., Roach, E. & Williams, J. A. Localization of saturable CCK binding sites in rat pancreatic islets by light and electron microscope autoradiography. Diabetes 34, 390-‐394 (1985).
133 Lo, C. M. et al. Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-‐deficient mice. Diabetes 60, 2000-‐2007, doi:10.2337/db10-‐0789 (2011).
134 Verspohl, E. J., Ammon, H. P., Williams, J. A. & Goldfine, I. D. Evidence that cholecystokinin interacts with specific receptors and regulates insulin release in isolated rat islets of Langerhans. Diabetes 35, 38-‐43 (1986).
135 Zawalich, W., Takuwa, N., Takuwa, Y., Diaz, V. A. & Rasmussen, H. Interactions of cholecystokinin and glucose in rat pancreatic islets. Diabetes 36, 426-‐433 (1987).
136 Malm, D., Giaever, A., Vonen, B. & Florholmen, J. Cholecystokinin and somatostatin modulate the glucose-‐induced insulin secretion by different mechanisms in pancreatic islets. A study on phospholipase C activity and calcium requirement. Scandinavian Journal of Clinical & Laboratory Investigation 53, 671-‐676 (1993).
137 Cheung, G. W., Kokorovic, A., Lam, C. K., Chari, M. & Lam, T. K. Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab 10, 99-‐109, doi:10.1016/j.cmet.2009.07.005 (2009).
138 Wang, P. Y. et al. Upper intestinal lipids trigger a gut-‐brain-‐liver axis to regulate glucose production. Nature 452, 1012-‐1016, doi:10.1038/nature06852 (2008).
139 Kokorovic, A. et al. Duodenal mucosal protein kinase C-‐delta regulates glucose production in rats. Gastroenterology 141, 1720-‐1727, doi:10.1053/j.gastro.2011.06.042 (2011).
140 Chang, C. H., Chey, W. Y. & Chang, T. M. Cellular mechanism of sodium oleate-‐stimulated secretion of cholecystokinin and secretin. American Journal of Physiology: Gastrointestinal & Liver Physiology 279, G295-‐303 (2000).
141 Takahashi, A. et al. Involvement of calmodulin and protein kinase C in cholecystokinin release by bombesin from STC-‐1 cells. Pancreas 21, 231-‐239 (2000).
142 Rogers, R. C. & Hermann, G. E. Mechanisms of action of CCK to activate central vagal afferent terminals. Peptides 29, 1716-‐1725, doi:10.1016/j.peptides.2008.06.023 (2008).
143 Rasmussen, B. A. et al. Duodenal activation of cAMP-‐dependent protein kinase induces vagal afferent firing and lowers glucose production in rats. Gastroenterology 142, 834-‐843 e833, doi:10.1053/j.gastro.2011.12.053 (2012).
74
144 Duca, F. A., Bauer, P. V., Hamr, S. C. & Lam, T. K. Glucoregulatory Relevance of Small Intestinal Nutrient Sensing in Physiology, Bariatric Surgery, and Pharmacology. Cell Metab 22, 367-‐380, doi:10.1016/j.cmet.2015.07.003 (2015).
145 Covasa, M. & Ritter, R. C. Reduced sensitivity to the satiation effect of intestinal oleate in rats adapted to high-‐fat diet. Am J Physiol 277, R279-‐285 (1999).
146 Boyd, K. A. et al. High-‐fat diet effects on gut motility, hormone, and appetite responses to duodenal lipid in healthy men. American Journal of Physiology: Gastrointestinal & Liver Physiology 284, G188-‐196, doi:10.1152/ajpgi.00375.2002 (2003).
147 French, S. J., Murray, B., Rumsey, R. D., Fadzlin, R. & Read, N. W. Adaptation to high-‐fat diets: effects on eating behaviour and plasma cholecystokinin. Br J Nutr 73, 179-‐189 (1995).
148 Richards, P. et al. High fat diet impairs the function of glucagon-‐like peptide-‐1 producing L-‐cells. Peptides, doi:10.1016/j.peptides.2015.06.006 (2015).
149 Sundaresan, S. et al. CD36-‐dependent signaling mediates fatty acid-‐induced gut release of secretin and cholecystokinin. FASEB J 27, 1191-‐1202, doi:10.1096/fj.12-‐217703 (2013).
150 Duca, F. A., Swartz, T. D., Sakar, Y. & Covasa, M. Decreased intestinal nutrient response in diet-‐induced obese rats: role of gut peptides and nutrient receptors. Int J Obes (Lond) 37, 375-‐381, doi:10.1038/ijo.2012.45 (2013).
151 Savastano, D. M. & Covasa, M. Adaptation to a high-‐fat diet leads to hyperphagia and diminished sensitivity to cholecystokinin in rats. J Nutr 135, 1953-‐1959 (2005).
152 Covasa, M., Grahn, J. & Ritter, R. C. Reduced hindbrain and enteric neuronal response to intestinal oleate in rats maintained on high-‐fat diet. Auton Neurosci 84, 8-‐18, doi:10.1016/S1566-‐0702(00)00176-‐4 (2000).
153 Swartz, T. D., Duca, F. A. & Covasa, M. Differential feeding behavior and neuronal responses to CCK in obesity-‐prone and -‐resistant rats. Brain Res 1308, 79-‐86, doi:10.1016/j.brainres.2009.10.045 (2010).
154 Covasa, M., Grahn, J. & Ritter, R. C. High fat maintenance diet attenuates hindbrain neuronal response to CCK. Regul Pept 86, 83-‐88 (2000).
155 van der Klaauw, A. A. et al. High protein intake stimulates postprandial GLP1 and PYY release. Obesity (Silver Spring) 21, 1602-‐1607, doi:10.1002/oby.20154 (2013).
156 Rezek, M. & Novin, D. Duodenal nutrient infusion: effects on feeding in intact and vagotomized rabbits. J Nutr 106, 812-‐820 (1976).
157 Bowen, J., Noakes, M. & Clifton, P. M. Appetite regulatory hormone responses to various dietary proteins differ by body mass index status despite similar reductions in ad libitum energy intake. Journal of Clinical Endocrinology & Metabolism 91, 2913-‐2919, doi:10.1210/jc.2006-‐0609 (2006).
158 Lejeune, M. P., Westerterp, K. R., Adam, T. C., Luscombe-‐Marsh, N. D. & Westerterp-‐Plantenga, M. S. Ghrelin and glucagon-‐like peptide 1 concentrations, 24-‐h satiety, and energy and substrate metabolism during a high-‐protein diet and measured in a respiration chamber. Am J Clin Nutr 83, 89-‐94 (2006).
159 Fromentin, G. et al. Peripheral and central mechanisms involved in the control of food intake by dietary amino acids and proteins. Nutr Res Rev 25, 29-‐39, doi:10.1017/S0954422411000175 (2012).
75
160 Moran, L. J. et al. The satiating effect of dietary protein is unrelated to postprandial ghrelin secretion. Journal of Clinical Endocrinology & Metabolism 90, 5205-‐5211, doi:10.1210/jc.2005-‐0701 (2005).
161 Steinert, R. E. et al. Effects of intraduodenal infusion of L-‐tryptophan on ad libitum eating, antropyloroduodenal motility, glycemia, insulinemia, and gut peptide secretion in healthy men. Journal of Clinical Endocrinology & Metabolism 99, 3275-‐3284, doi:10.1210/jc.2014-‐1943 (2014).
162 Meyer, J. H., Hlinka, M., Tabrizi, Y., DiMaso, N. & Raybould, H. E. Chemical specificities and intestinal distributions of nutrient-‐driven satiety. Am J Physiol 275, R1293-‐1307 (1998).
163 Ryan, A. T. et al. Effects of intraduodenal lipid and protein on gut motility and hormone release, glycemia, appetite, and energy intake in lean men. Am J Clin Nutr 98, 300-‐311, doi:10.3945/ajcn.113.061333 (2013).
164 Tome, D., Schwarz, J., Darcel, N. & Fromentin, G. Protein, amino acids, vagus nerve signaling, and the brain. Am J Clin Nutr 90, 838S-‐843S, doi:10.3945/ajcn.2009.27462W (2009).
165 Faipoux, R., Tome, D., Gougis, S., Darcel, N. & Fromentin, G. Proteins activate satiety-‐related neuronal pathways in the brainstem and hypothalamus of rats. J Nutr 138, 1172-‐1178 (2008).
166 Smeets, A. J., Soenen, S., Luscombe-‐Marsh, N. D., Ueland, O. & Westerterp-‐Plantenga, M. S. Energy expenditure, satiety, and plasma ghrelin, glucagon-‐like peptide 1, and peptide tyrosine-‐tyrosine concentrations following a single high-‐protein lunch. J Nutr 138, 698-‐702 (2008).
167 Dyer, J., Salmon, K. S., Zibrik, L. & Shirazi-‐Beechey, S. P. Expression of sweet taste receptors of the T1R family in the intestinal tract and enteroendocrine cells. Biochem Soc Trans 33, 302-‐305, doi:10.1042/BST0330302 (2005).
168 Daly, K. et al. Sensing of amino acids by the gut-‐expressed taste receptor T1R1-‐T1R3 stimulates CCK secretion. American Journal of Physiology: Gastrointestinal & Liver Physiology 304, G271-‐282, doi:10.1152/ajpgi.00074.2012 (2013).
169 Broer, S. The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition. IUBMB Life 61, 591-‐599, doi:10.1002/iub.210 (2009).
170 Broer, A. et al. Impaired nutrient signaling and body weight control in a Na+ neutral amino acid cotransporter (Slc6a19)-‐deficient mouse. J Biol Chem 286, 26638-‐26651, doi:10.1074/jbc.M111.241323 (2011).
171 Wolff, B. S., Meirelles, K., Meng, Q., Pan, M. & Cooney, R. N. Roux-‐en-‐Y gastric bypass alters small intestine glutamine transport in the obese Zucker rat. American Journal of Physiology: Gastrointestinal & Liver Physiology 297, G594-‐601, doi:10.1152/ajpgi.00104.2009 (2009).
172 Choi, S., Lee, M., Shiu, A. L., Yo, S. J. & Aponte, G. W. Identification of a protein hydrolysate responsive G protein-‐coupled receptor in enterocytes. American Journal of Physiology: Gastrointestinal & Liver Physiology 292, G98-‐G112, doi:10.1152/ajpgi.00295.2006 (2007).
173 Choi, S. et al. GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-‐1 cells. American Journal of Physiology: Gastrointestinal & Liver Physiology 292, G1366-‐1375, doi:10.1152/ajpgi.00516.2006 (2007).
76
174 Wang, M., Yao, Y., Kuang, D. & Hampson, D. R. Activation of family C G-‐protein-‐coupled receptors by the tripeptide glutathione. J Biol Chem 281, 8864-‐8870, doi:10.1074/jbc.M512865200 (2006).
175 Nakajima, S., Hira, T., Sufian, M. K., Eto, Y. & Hara, H. Calcium-‐sensing receptor is a sensor for dietary peptides to stimulate cholecystokinin secretion in the enteroendocrine cell line STC-‐1. Regul Pept 164, 45, doi:10.1016/j.regpep.2010.07.118 (2010).
176 Nakajima, S., Hira, T. & Hara, H. Calcium-‐sensing receptor mediates dietary peptide-‐induced CCK secretion in enteroendocrine STC-‐1 cells. Mol Nutr Food Res 56, 753-‐760, doi:10.1002/mnfr.201100666 (2012).
177 Diakogiannaki, E. et al. Oligopeptides stimulate glucagon-‐like peptide-‐1 secretion in mice through proton-‐coupled uptake and the calcium-‐sensing receptor. Diabetologia 56, 2688-‐2696, doi:10.1007/s00125-‐013-‐3037-‐3 (2013).
178 Jeanningros, R. Vagal unitary responses to intestinal amino acid infusions in the anesthetized cat: a putative signal for protein induced satiety. Physiology & Behavior 28, 9-‐21 (1982).
179 Lindgren, O. et al. Incretin effect after oral amino acid ingestion in humans. Journal of Clinical Endocrinology & Metabolism 100, 1172-‐1176, doi:10.1210/jc.2014-‐3865 (2015).
180 Eastwood, C., Maubach, K., Kirkup, A. J. & Grundy, D. The role of endogenous cholecystokinin in the sensory transduction of luminal nutrient signals in the rat jejunum. Neurosci Lett 254, 145-‐148 (1998).
181 Darcel, N. P., Liou, A. P., Tome, D. & Raybould, H. E. Activation of vagal afferents in the rat duodenum by protein digests requires PepT1. J Nutr 135, 1491-‐1495 (2005).
182 Cuber, J. C. et al. Luminal CCK-‐releasing factors in the isolated vascularly perfused rat duodenojejunum. Am J Physiol 259, G191-‐197 (1990).
183 Nemoz-‐Gaillard, E. et al. Regulation of cholecystokinin secretion by peptones and peptidomimetic antibiotics in STC-‐1 cells. Endocrinology 139, 932-‐938, doi:10.1210/endo.139.3.5802 (1998).
184 Murai, A., Noble, P. M., Deavall, D. G. & Dockray, G. J. Control of c-‐fos expression in STC-‐1 cells by peptidomimetic stimuli. Eur J Pharmacol 394, 27-‐34 (2000).
185 Cordier-‐Bussat, M. et al. Peptones stimulate cholecystokinin secretion and gene transcription in the intestinal cell line STC-‐1. Endocrinology 138, 1137-‐1144, doi:10.1210/endo.138.3.5023 (1997).
186 McConnell, E. L., Basit, A. W. & Murdan, S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-‐vivo experiments. Journal of Pharmacy & Pharmacology 60, 63-‐70, doi:10.1211/jpp.60.1.0008 (2008).
187 Schwartz, G. J. et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8, 281-‐288, doi:10.1016/j.cmet.2008.08.005 (2008).
188 Matthews, D. M., Muir, G. G. & Baron, D. N. Estimation of Alpha-‐Amino Nitrogen in Plasma and Urine by the Colorimetric Ninhydrin Reaction. J Clin Pathol 17, 150-‐153 (1964).
189 Schemmel, R., Mickelsen, O. & Gill, J. L. Dietary obesity in rats: Body weight and body fat accretion in seven strains of rats. J Nutr 100, 1041-‐1048 (1970).
77
190 Ussar, S. et al. Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome. Cell Metab 22, 516-‐530, doi:10.1016/j.cmet.2015.07.007 (2015).
191 Lozner, E. L., Winkler, A. W., Taylor, F. H. & Peters, J. P. The Intravenous Glucose Tolerance Test. J Clin Invest 20, 507-‐515, doi:10.1172/JCI101243 (1941).
192 Smith, D. et al. In vivo glucose metabolism in the awake rat: tracer and insulin clamp studies. Metabolism: Clinical & Experimental 36, 1167-‐1174 (1987).
193 Greenberg, D., Smith, G. P. & Gibbs, J. Intraduodenal infusions of fats elicit satiety in sham-‐feeding rats. Am J Physiol 259, R110-‐118 (1990).
194 Tremblay, F., Lavigne, C., Jacques, H. & Marette, A. Role of dietary proteins and amino acids in the pathogenesis of insulin resistance. Annu Rev Nutr 27, 293-‐310, doi:10.1146/annurev.nutr.25.050304.092545 (2007).
195 Su, Y. et al. Hypothalamic leucine metabolism regulates liver glucose production. Diabetes 61, 85-‐93, doi:10.2337/db11-‐0857 (2012).
196 Tanaka, K., Inoue, S., Nagase, H., Takamura, Y. & Niijima, A. Amino acid sensors sensitive to alanine and leucine exist in the hepato-‐portal system in the rat. J Auton Nerv Syst 31, 41-‐46 (1990).
197 Niijima, A. & Meguid, M. M. An electrophysiological study on amino acid sensors in the hepato-‐portal system in the rat. Obes Res 3 Suppl 5, 741S-‐745S (1995).
198 Hellier, M. D., Holdsworth, C. D., McColl, I. & Perrett, D. Dipeptide absorption in man. Gut 13, 965-‐969 (1972).
199 Thamotharan, M., Bawani, S. Z., Zhou, X. & Adibi, S. A. Mechanism of dipeptide stimulation of its own transport in a human intestinal cell line. Proc Assoc Am Physicians 110, 361-‐368 (1998).
200 Anderson, G. H. et al. Relation between estimates of cornstarch digestibility by the Englyst in vitro method and glycemic response, subjective appetite, and short-‐term food intake in young men. Am J Clin Nutr 91, 932-‐939, doi:10.3945/ajcn.2009.28443 (2010).
201 Raybould, H. E., Zittel, T. T., Holzer, H. H., Lloyd, K. C. & Meyer, J. H. Gastroduodenal sensory mechanisms and CCK in inhibition of gastric emptying in response to a meal. Digestive Diseases & Sciences 39, 41S-‐43S (1994).
202 Rabinowitz, D., Merimee, T. J., Maffezzoli, R. & Burgess, J. A. Patterns of hormonal release after glucose, protein, and glucose plus protein. Lancet 2, 454-‐456 (1966).
203 Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R. & Niijima, A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-‐1. Am J Physiol 271, E808-‐813 (1996).
204 Schmid, R., Schusdziarra, V., Schulte-‐Frohlinde, E., Maier, V. & Classen, M. Effect of CCK on insulin, glucagon, and pancreatic polypeptide levels in humans. Pancreas 4, 653-‐661 (1989).
205 Knauf, C. et al. Role of central nervous system glucagon-‐like Peptide-‐1 receptors in enteric glucose sensing. Diabetes 57, 2603-‐2612, doi:10.2337/db07-‐1788 (2008).
206 Lebovitz, H. E. et al. Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-‐mediated stimulation. A randomized blinded cross-‐over trial. Physiol Rep 3, doi:10.14814/phy2.12456 (2015).
207 Kondoh, T. & Torii, K. Brain activation by umami substances via gustatory and visceral signaling pathways, and physiological significance. Biological & Pharmaceutical Bulletin 31, 1827-‐1832 (2008).
78
208 Steinert, R. E., Landrock, M. F., Horowitz, M. & Feinle-‐Bisset, C. Effects of Intraduodenal Infusions of L-‐phenylalanine and L-‐glutamine on Antropyloroduodenal Motility and Plasma Cholecystokinin in Healthy Men. Journal of Neurogastroenterology & Motility 21, 404-‐413, doi:10.5056/jnm14143 (2015).
209 Cote, C. D. et al. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med 21, 498-‐505, doi:10.1038/nm.3821 (2015).
210 Hu, Y. et al. Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine. Mol Pharm 5, 1122-‐1130 (2008).
211 Arrieta-‐Cruz, I., Su, Y. & Gutierrez-‐Juarez, R. Suppression of Endogenous Glucose Production by Isoleucine and Valine and Impact of Diet Composition. Nutrients 8, doi:10.3390/nu8020079 (2016).
212 Stengel, A. et al. High-‐protein diet selectively reduces fat mass and improves glucose tolerance in Western-‐type diet-‐induced obese rats. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 305, R582-‐591, doi:10.1152/ajpregu.00598.2012 (2013).
213 Zhang, Y. et al. Increasing dietary leucine intake reduces diet-‐induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes 56, 1647-‐1654, doi:10.2337/db07-‐0123 (2007).
214 Nuttall, F. Q., Mooradian, A. D., Gannon, M. C., Billington, C. & Krezowski, P. Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. Diabetes Care 7, 465-‐470 (1984).
215 Gannon, M. C., Nuttall, F. Q., Neil, B. J. & Westphal, S. A. The insulin and glucose responses to meals of glucose plus various proteins in type II diabetic subjects. Metabolism: Clinical & Experimental 37, 1081-‐1088 (1988).
216 Manders, R. J. et al. Co-‐ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr 82, 76-‐83 (2005).